The 356 evidence claims of the lipedema pilot registry. Each is an addressable object with an evidence-certainty rating (GRADE), a knowledge state, and explicit gaps. Consensus is tracked separately and added over time.
Clinical signs that help diagnose lipedema and distinguish it from lymphedema include a usually negative Kaposi-Stemmer sign, the cuff sign with foot sparing, fat painful on palpation, easy bruising, and minimal pitting edema (Stemmer becomes positive only when secondary lymphedema/lipolymphedema develops).
Evidence certainty: very low (GRADE) · 2 source(s) · 2 by Amato
In the Brazilian Delphi consensus, experts agreed that lipedema and obesity do not have a causal relationship and that BMI is of limited value in differentiating lipedema from obesity.
Evidence certainty: very low (GRADE) · 1 source(s) · 1 by Amato
Lipedema is a multifactorial disorder whose symptoms are closely linked to female hormonal transitions (puberty, pregnancy, menopause) and to chronic low-grade inflammation, on a polygenic predisposition.
Evidence certainty: very low (GRADE) · 2 source(s) · 2 by Amato
In women undergoing venous ultrasound, dermal/subcutaneous thickness measurements at the pre-tibial region, anterior thigh and lateral leg can distinguish clinically diagnosed lipedema from non-lipedema in the lower limbs.
For ultrasound diagnosis of lower-limb lipedema, subcutaneous thickness cutoffs of >11.7 mm (pre-tibial), >17.9 mm (anterior thigh), >8.4 mm (lateral leg) and >7.0 mm (medial supramalleolar) provide reproducible reference values.
Because obesity is commonly defined by BMI alone (which disregards fat distribution), lipedema is frequently underdiagnosed when workup stops at an established obesity diagnosis; ~81% of lipedema patients are classified overweight/obese by BMI.
The Brazilian Portuguese lipedema symptoms questionnaire (QuASiL) was translated, culturally adapted and validated, showing high comprehension and symptom-intensity scores that correlate with limb volume by segmental bioimpedance.
Qualitative ultrasound patterns of the dermis and hypodermis (Lipedema Dermal and Hypodermal Classification, LDHC) describe structural changes (septal alteration, echogenic nodules, dermal-hypodermal junction disruption) that may correspond to stages of inflammation and fibrosis.
Echogenic (hyperechoic) subcutaneous nodules in lipedema can be subclassified into at least four morphological variants (LDHC 3a-3d) whose distribution corresponds most strongly to the patient's most painful site.
During the standard venous Doppler mapping exam, lipedema can be identified by ultrasound: dermal–subcutaneous thickness at predefined lower-limb points is roughly twice as high in women with lipedema as in controls, with applicable ROC cut-offs — making venous ultrasound an opportunity to screen for lipedema.
Lipedema occurs in men with the classical phenotype (bilateral, symmetrical, foot-sparing lower-limb fat accumulation, negative Stemmer sign), although it almost exclusively affects women and male occurrence is rare.
Women meeting lipedema screening criteria have a higher prevalence of positive ADHD self-report (ASRS-18) than women without lipedema (76.9% vs 54%; RR 1.424).
Secondary lymphedema (lipolymphedema) can develop as a complication of advanced lipedema due to chronic lymphatic overload, with lymph stasis becoming more evident at advanced disease stages.
Evidence certainty: very low (GRADE) · 1 source(s) · 1 by Amato
Increased limb adipose tissue in lipedema can impair mobility and hinder activities of daily living, contributing to functional disability beyond the cosmetic burden.
Evidence certainty: very low (GRADE) · 1 source(s) · 1 by Amato
Thyroid disorders may be more frequent in lipedema than in lymphedema, with a cross-sectional cohort reporting thyroid disease in 24.4% of lipedema vs 14.89% of lymphedema patients.
Lipedema and fibromyalgia frequently co-occur: a cross-sectional study found lipedema in 50% of women meeting ACR fibromyalgia criteria, with longer fibromyalgia diagnostic delay and younger menarche as risk factors.
Women with clinically diagnosed lipedema show a higher prevalence of the celiac-associated HLA-DQ2/DQ8 haplotypes than the general population (any HLA 61.1% vs 53.7%; both haplotypes 7.4% vs 1.2%).
In women with lipedema, food-specific IgG testing shows a paradox: a slightly higher number of positive food reactions despite markedly lower total IgG (1747 vs 2975 AU; p<0.001).
In a nationally representative NHANES sample, women with serologically confirmed celiac disease had significantly lower gynoid percent fat than non-celiac women (39.5% vs 42.6%; -7.4%; p=0.0007).
The reduced gynoid adiposity associated with celiac disease in NHANES persisted among overweight/obese women (-8.7% overall, p=0.005; -11.3% in obese, p=0.039), arguing against leanness/malnutrition as the sole explanation.
In NHANES women, a DXA-defined lipedema-like phenotype (leg-to-trunk fat ratio >90th percentile) was associated with a favorable immunometabolic profile, including 44.2% lower HOMA-IR (p<0.001) and 7.6% lower neutrophil-to-lymphocyte ratio (p=0.012).
In NHANES women aged 20-59, a lipedema-like peripheral fat distribution was inversely associated with cancer prevalence: each 1-SD increase in leg-to-trunk fat ratio was associated with 20% lower adjusted odds of cancer (OR 0.795; 95%CI 0.666-0.948; p=0.011).
The inverse association between lipedema-like peripheral fat distribution and cancer prevalence was most robust in women without obesity (OR 0.67 per 1-SD LTR; 95%CI 0.53-0.85; p=0.0007).
In women with lipedema, liposuction (tumescent/large-volume) produces significant post-operative reductions in spontaneous pain, edema, bruising, mobility impairment and quality-of-life impairment versus pre-operative status.
Evidence certainty: high (GRADE) · 8 source(s) · 1 by Amato
Liposuction for lipedema by an experienced team is a safe procedure with a low rate of major complications (no DVT, PE, necrosis or severe anemia observed; minor complications ~1%), though seroma occurs in ~18%.
In lipedema liposuction, higher relative aspirated fat volume (per 1% body weight) and concomitant minor surgical procedures are independent risk factors for postoperative seroma.
Ultrasound-assisted liposuction may reduce postoperative seroma risk in lipedema surgery (0 seromas among ultrasound-assisted cases vs 18.4% otherwise), although this finding is hypothesis-generating only.
In women with lipedema, a low-carbohydrate high-fat (ketogenic) diet significantly reduces body weight, BMI and waist/hip circumferences over a mean of ~16 weeks.
Evidence certainty: high (GRADE) · 1 source(s) · 1 by Amato
An individualized, multidisciplinary approach combining conservative anti-inflammatory therapy with staged liposuction (rather than liposuction as a sole cure) is proposed as the optimal treatment model for lipedema.
Evidence certainty: high (GRADE) · 2 source(s) · 2 by Amato
In women with lipedema, hormonal contraceptive use is associated with self-reported symptom worsening (58.8% of users; 15.1% reporting symptom onset coinciding with contraceptive initiation).
There is no scientific evidence supporting gestrinone for lipedema: a PRISMA systematic review identified zero clinical trials, observational studies or case reports evaluating it, particularly as subcutaneous implants.
Evidence certainty: high (GRADE) · 1 source(s) · 1 by Amato
Lipedema is defined by a disproportionate, symmetrical accumulation of subcutaneous adipose tissue in the limbs relative to the trunk that is characteristically resistant to conventional weight-loss methods (diet and exercise), distinguishing it from common obesity.
Evidence certainty: very low (GRADE) · 1 source(s) · 1 by Amato
Lipedema can negatively impact mental health and quality of life, and delayed diagnosis or late treatment worsens symptom burden and psychological well-being.
Evidence certainty: very low (GRADE) · 1 source(s) · 1 by Amato
The diagnosis of lipedema is primarily clinical, relying on the patient's medical history, physical examination, and exclusion of differential diagnoses (notably obesity and lymphedema).
Conservative management (lifestyle and dietary changes, compression therapy, low-impact exercise) is first-line for lipedema, and surgery (liposuction) should be considered only after an adequate trial of conservative treatment, prioritizing mobility and symptom relief over aesthetic outcomes.
Evidence certainty: high (GRADE) · 5 source(s) · 1 by Amato
Lipedema was first delineated as a distinct clinical syndrome by Allen and Hines at the Mayo Clinic in 1940, who coined the term and described the disproportionate, bilateral, foot-sparing leg fat with edema that defines it.
Evidence certainty: very low (GRADE) · 1 source(s)
Allen EV, Hines EA Jr. Lipedema of the legs: a syndrome characterized by fat legs and edema. Proc Staff Meet Mayo Clin 1940;15:184-7
Gaps: Historical descriptive report predating modern diagnostic criteria and imaging.
The clinical syndrome was consolidated in 1951 when Wold, Hines and Allen reported a large case series (about 119 patients) detailing lipedema's orthostatic edema, pain and strong predominance in women.
Evidence certainty: very low (GRADE) · 1 source(s)
Wold LE, Hines EA Jr, Allen EV. Lipedema of the legs: a syndrome characterized by fat legs and orthostatic edema. Ann Intern Med 1951;34(5):1243-50
Gaps: Uncontrolled historical case series; predates modern criteria.
The first surgical approach to the disproportionate gynoid/trochanteric fat deposits characteristic of lipedema is attributed to Ivo Pitanguy's 1964 description of the surgical correction of 'trochanteric lipodystrophy' (the 'saddlebag' deformity).
Evidence certainty: very low (GRADE) · 1 source(s)
Gaps: 'First surgery' is an interpretive attribution: the 1964 report addresses trochanteric lipodystrophy (disproportionate gynoid fat), predates modern lipedema criteria, and was excisional rather than liposuction.
Modern surgical treatment of lipedema is tumescent liposuction with blunt vibrating microcannulas, established from the 2000s; single-centre cohorts report sustained reductions in pain, edema and need for conservative therapy at up to 12 years of follow-up.
The article reports that patients with lipedema frequently exhibit connective tissue laxity and hypermobility, suggesting a potential association between lipedema and increased prevalence of joint hypermobility.
Evidence certainty: very low (GRADE) · 1 source(s)
The article discusses the high prevalence of generalized joint hypermobility in women with lipedema, suggesting a link that may increase joint loading and contribute to knee pain.
Evidence certainty: very low (GRADE) · 1 source(s)
The article investigates the relationship between joint hypermobility and adipose disorders, including lipedema, but does not provide direct evidence on whether lipedema increases the prevalence of joint hypermobility.
The article discusses the effects of a modified Mediterranean diet on lipoedema patients, noting improvements in their ability to perform daily activities with less fatigue, pain, and anxiety, but does not directly establish a link between lipoedema and fibromyalgia or other chronic-pain conditions.
The article provides a narrative review of lipedema and discusses treatment protocols, including liposuction, but does not provide definitive evidence on its effectiveness and safety specifically for lipedema.
Evidence certainty: very low (GRADE) · 1 source(s)
The article provides a literature review on lipedema, discussing its pathological conditions, treatments including surgical options, and the need for recognition of lipedema as a distinct clinical entity, which relates to the historical milestones in its description and treatment.
Evidence certainty: very low (GRADE) · 1 source(s)
This article discusses the use of ultrasound in optimizing liposuction for lipedema patients, highlighting advancements in surgical techniques but does not detail historical milestones in the description and treatment of lipedema.
Evidence certainty: very low (GRADE) · 1 source(s)
A narrative review of 2020–2025 evidence concludes that systematic lipedema screening is necessary when studying pain–inflammation relationships in women with obesity, because unrecognized lipedema may cluster pain within peripheral fat phenotypes and bias comparisons between android and gynoid obesity groups.
Evidence certainty: very low (GRADE) · 1 source(s)
In a cross-sectional study of 115 female patients in Saudi Arabia, only 71% received a clinical diagnosis of lipedema despite presenting to a specialized clinic, and the study authors characterize this as a high underdiagnosis rate requiring increased awareness.
In a cohort of 1803 Spanish lipedema patients, 60.6% were diagnosed during reproductive years with a mean age of 42.9 years, and the study presents a novel clinical assessment approach including multiple comorbidity markers (e.g., suspected high intestinal permeability in 99%, bilateral trochanteric pain in 97.4%, ligamentous hyperlaxity in 95.8%) that may help physicians better identify and understand the condition.
Reviews of imaging and measurement tools for lipedema find multiple modalities in use (ultrasound, lymphoscintigraphy, CT, MRI/MR-lymphangiography, DXA) but inconsistent protocols, measurement locations, and outcome analysis, with limited clinimetric reporting from small heterogeneous cohorts — preventing recommendation of any single tool for clinical practice.
Dutch lipedema guidelines conclude that lipedema is frequently misdiagnosed or wrongly classified as an aesthetic problem, and recommend a minimum data set of repeated clinical measurements (waist circumference, limb circumferences, BMI, and psychosocial distress scoring) to ensure early detection.
Evidence certainty: very low (GRADE) · 1 source(s)
Lipedema is often unrecognized or misdiagnosed despite an estimated prevalence of 10% in the overall female population, and diagnosis currently relies on clinical grounds alone due to the lack of specific biomarkers or objective measuring instruments.
Evidence certainty: very low (GRADE) · 4 source(s)
Review analysis indicates that lymphedema and lipedema diverge in time course, molecular regulators, pathophysiology, and genetics, suggesting unique routes to interstitial fluid accumulation and inflammation despite shared clinical features of edema, adipose expansion, and fibrosis.
Evidence certainty: very low (GRADE) · 1 source(s)
Lipedema adipose tissue shows distinct histopathologic features (adipocyte hypertrophy, increased intercellular fibrosis, macrophage infiltration), aberrant lipid metabolism, and a unique adipogenesis gene expression profile compared to BMI-matched controls, differentiating it from obesity and lymphedema.
Exosome, cytokine, lipidomic, and metabolomic profiling studies suggest lipedema is a condition distinct from obesity and lymphedema, characterized by hyperproliferation of fat cells, fibrosis, inflammation, and resistance to conventional weight-loss interventions.
Evidence certainty: very low (GRADE) · 1 source(s)
In a national survey of 707 U.S. women with lipedema, the mean age was 48.6 years and mean BMI was 40.9 kg/m², with symptom onset most commonly at puberty (48.0%) or pregnancy (41.2%), and the condition exclusively affected women in this sample.
In a survey of 209 German female lipedema patients who underwent liposuction, the average age was 38.5 years, first manifestation occurred at age 16, and diagnosis took a mean of 15 years to achieve, with comorbidities including hypothyroidism (35.9%) and depression (23.0%) at rates exceeding general population prevalence.
Lipedema is a serious disease with undetermined genetic background that affects women, first described as a syndrome in 1940, and is neither a cosmetic problem nor a lifestyle issue, though its true prevalence and incidence remain poorly defined in the literature.
Evidence certainty: very low (GRADE) · 1 source(s)
In a retrospective series of 106 lipedema patients who underwent liposuction, the cohort was exclusively female with a median BMI of 31.6 kg/m², and showed elevated prevalence of obesity, hypothyroidism, migraine, and depression compared to non-lipedema populations, while diabetes (5%) and dyslipidemia (7%) prevalence were unexpectedly low.
In a Swiss referral centre cohort of 381 women with lipedema (mean age 41.9 years), 49.9% reported a family history, 62.2% reported symptom onset during adolescence, and 92.1% had comorbidities, with pain affecting 87.9% and significantly reduced quality of life in the majority.
In a cohort of 360 Italian women with lipedema of the lower limbs (stages 1–3), the condition was found exclusively in women and was associated with comorbidities including vitamin D insufficiency, chronic venous disease, and dyslipidemia.
3D ultrasound (17 MHz) identified specific structural features in lipedema patients (stages I-III) including adipose lobule hypertrophy, fibrotic connective septa, thickened superficial fascia, and fluid anechogenicity along the superficial fascia not previously detected by 2D ultrasound.
Ultrasound, along with DXA and MRI, provides valuable diagnostic insights in lipedema but is not considered definitive for diagnosis or classification.
Ultra Micro Angiography (UMA) ultrasound technique visualized subcutaneous microvascular structures in lipedema patients with superior detail compared to conventional color Doppler, revealing grade 2–3 microvascular flow patterns in most of the 25 lipedema patients studied.
High-resolution 20 MHz cutaneous ultrasonography correctly differentiated lymphedema from lipedema in all cases, with lymphedema showing significantly increased dermal thickness and diffuse hypoechogenicity, while lipedema showed no significant difference in dermal thickness compared to controls and only localized upper-dermal hypoechogenicity at the ankle.
Shear-wave elastography (SWE) measurements of thigh tissue stiffness correlate with pain and neuropathic pain scores in lipedema patients, suggesting SWE can quantify tissue alterations beyond subcutaneous fat thickness alone.
Evidence certainty: very low (GRADE) · 1 source(s)
Histological analysis of lipedema hand and foot tissue reveals perineurial/endoneurial macrophage infiltration (nerve-associated inflammation) concurrent with increased microvascular density, perivascular fibrosis, adipocyte hypertrophy, and mast cell infiltration, suggesting pain in lipedema involves both vascular and neurogenic inflammatory mechanisms.
Evidence certainty: very low (GRADE) · 1 source(s)
In lipedema subcutaneous adipose tissue, interstitial fibrosis precedes adipocyte hypertrophy (present at stage I), crown-like structures appear at all stages, IL-6 and TNF are upregulated at stages II–III in affected thighs, macrophage polarization shifts from M2-dominant (anti-inflammatory) at stage I toward M1-like (pro-inflammatory) at stage III, and VEGFC is upregulated in advanced disease—collectively delineating a stage-dependent inflammatory and fibrotic progression in affected tissue.
Lipedema thigh skin shows significantly increased dermal interstitial spaces (~46% vs 42% in controls, p=0.003) and abnormal vessel phenotype (microangiopathy) concentrated in hydrostatic-pressure-exposed areas, with elevated tissue sodium proposed as a mechanism of endothelial glycocalyx damage leading to endothelial inflammation and microangiopathy.
In females with lipedema and obesity, reductions in pain after a low-carbohydrate diet were not significantly associated with changes in systemic inflammatory markers (hsCRP, TNF-α, MIP-1β) or fibrosis-associated markers (TGF-β1/2/3), suggesting systemic inflammation does not mediate pain reduction in lipedema, and that localized adipose tissue inflammation may be more relevant.
In a case of atypical lipedema with skin hypoperfusion and ulceration, the authors propose that inflammation and microangiopathy explain the associated pain, while accumulation of matrix proteins (GAGs) and sodium leads to microvascular fragility, petechiae, bruising, and tissue ischemia.
Evidence certainty: very low (GRADE) · 1 source(s)
The article proposes that peripheral nerve inflammation and sympathetic innervation abnormalities of subcutaneous adipose tissue—mediated by estrogen—are responsible for neuropathy and pain in lipedema, with elevated oxidative stress markers (malondialdehyde, protein carbonyls) and primary vasculo-lymphangiopathy contributing to the inflammatory milieu.
Evidence certainty: very low (GRADE) · 1 source(s)
Lipedema pain is causally linked to lipedema fat tissue with peripheral sensory changes identified as a contributing mechanism, while tissue weight and systemic inflammation are becoming less likely as primary causes.
Evidence certainty: very low (GRADE) · 1 source(s)
This hypothesis perspective proposes that extracellular vesicle-mediated crosstalk between endothelial cells, adipocytes, and immune cells drives localized inflammation and fibrosis in lipedema, with estrogen-linked signaling imprinting EV cargo in a sex-specific manner.
Evidence certainty: very low (GRADE) · 1 source(s)
Multi-omics analysis of lipedema tissue revealed local downregulation of inflammation-related factors alongside upregulation of mitochondrial and oxidative phosphorylation pathways, with minimal systemic inflammatory changes but altered sphingolipid, glutamic acid, and glutathione levels suggesting metabolic rather than classical inflammatory mechanisms.
In a cross-sectional survey of 354 women with lipedema, 35% (124/354) met ACR 2016 diagnostic criteria for fibromyalgia syndrome, and those with fibromyalgia had significantly higher anxiety, depression, and impaired quality of life compared to those without.
In a cross-sectional study comparing lipedema patients to sex-, age-, and BMI-matched population controls, 100% of lipedema patients reported pain (vs. 70.8% of controls), with 43.2% reporting severe pain-related disability in daily activities vs. 9.2% of controls, and strong correlation between pain severity and depressive symptoms (rho=0.612, p<0.001).
In a cohort of 860 lipedema patients, 99% had at least one comorbidity, including joint pain (58%), abnormal menstruation (43%), insomnia (36%), migraine (35%), allergies (33%), depression (31%), and lymphedema (30%), but fibromyalgia was not specifically reported among the listed comorbidities.
Lipedema is characterized as a painful fat disorder associated with fatigue (reported by ~75% of patients), joint abnormalities, psychosocial distress, and hypermobility in >50% of patients, but the article does not specifically quantify co-occurrence with fibromyalgia or other named chronic-pain conditions.
Women with lipedema show better glycemic control (lower HbA1c, higher adiponectin) compared to BMI-matched obese controls, but also exhibit higher LDL-cholesterol, elevated liver enzymes, greater oxidative stress, and a broad pro-inflammatory proteomic profile with 21 upregulated inflammatory proteins, suggesting a mixed rather than uniformly protective metabolic phenotype.
Lipedema is described as an estrogen-regulated polygenic disorder that manifests almost exclusively in women, with onset at hormonal transition phases (puberty, pregnancy, menopause), family aggregation in at least 16% of cases, and a pathological ERα/ERβ receptor pattern in white adipose tissue driving site-specific lipogenesis.
Evidence certainty: very low (GRADE) · 1 source(s)
A systematic review of lipedema pathology found that testosterone and estradiol showed no significant difference versus controls in plasma analysis, while the condition almost exclusively affects females and its fundamental etiology remains largely uncertain despite growing molecular and histological research.
In a case series of 24 lipedema patients treated with three liposuction techniques (TLAL, VASER, WAL), median BMI decreased from 29.65 to 26.95 kg/m², spontaneous pain VAS scores dropped from 7.10 to 2.00, edema scores from 8.50 to 2.10, and the overall complication rate was 12.5% with no major complications or mortality, with benefits sustained over a median 19-month follow-up.
A 62-year-old male patient with lipedema stage IV underwent three sessions of tumescent liposuction (total ~8,000 mL aspirated) with significant volume reduction, symptom resolution, and no recurrence over 2.5 years of follow-up despite 20 kg weight gain, with no major complications reported.
Evidence certainty: very low (GRADE) · 1 source(s)
A modified Mediterranean-ketogenic diet (<30g carbohydrates/day, 70% lipids) over 10 weeks produced significant reductions in body weight, total fat mass, and leg fat mass (including by DXA) in women with lipedema, with lean mass preserved, and the combination with carboxytherapy additionally reduced pain and improved quality of life.
A 7-month Mediterranean-style ketogenic diet (<50g carbohydrates/day) in women with lipedema significantly reduced body weight (86.1→74.1 kg), body fat, visceral fat, thigh and calf circumferences, and systemic inflammation markers (hs-CRP and IL-6), with reductions attributed to nutrient composition rather than caloric restriction alone.
A 7-month LCHF diet in women with lipedema produced significant reductions in body weight (~10.8 kg), fat mass (~7.4 kg), leg volume (~1395–1524 mL), ankle circumference (−1.0 cm), and pain scores (VAS 4.6→3.0), with outcomes comparable to overweight/obese controls except for greater ankle circumference reduction in the lipedema group.
A systematic review of 9 studies (269 women) found that ketogenic and low-carbohydrate diets consistently reduced weight and fat mass and improved pain and quality of life in lipedema, but evidence is limited by high risk of bias in 7 of 9 studies, lack of disease-stage stratification, absence of muscle mass assessment, and no significant reduction in inflammation (hsCRP) in the only low-risk RCT.
Complex decongestive therapy (CDT) combined with pneumatic compression applied 6 days/week for 1 month significantly reduced both extracellular (p=0.002) and intracellular (p=0.010) fluid volumes in 22 lipedema patients, suggesting CDT may slow disease progression since extracellular fluid accumulation is considered an accelerating factor.
A consensus statement from Italian scientific societies recommends that lipedema management combine physical exercise (aquatic, aerobic, strength training) with complete decongestive therapy (CDT) including manual lymphatic drainage, compression, and dietary interventions, with CDT plus exercise showing superior limb volume reduction compared to intermittent pneumatic compression plus exercise or exercise alone.
Evidence certainty: very low (GRADE) · 1 source(s)
Management of lipedema includes weight loss, edema control, complex decongestive physiotherapy, tumescent liposuction, and laser-assisted lipolysis, with tumescent liposuction reported as the preferred surgical option with long-lasting results.
Evidence certainty: very low (GRADE) · 1 source(s)
Lymphoscintigraphy in 19 lipedema patients revealed pathologic lymphatic transport (TI >10) in 63.2% of lower extremities, with significantly higher transport index scores in severe (stage 3/4) versus mild/moderate (stage 1/2) lipedema (mean TI 15.1 vs 9.7, p=0.049), indicating progressive lymphatic dysfunction associated with clinical severity.
In early-stage (I-II) lipedema, near-infrared fluorescence lymphatic imaging reveals dilated lymphatic vessels and increased propulsion rates but no dermal backflow, indicating that lymphatic failure is absent in early lipedema but likely contributes to progression toward lipolymphedema.
In a retrospective review of 250 lower extremity lymphedema cases, 9 patients with lipedema showed bilateral symmetric swelling sparing the feet, absent Stemmer sign, and consistent fat pads anterior to the lateral malleoli, distinguishing lipedema as a separate clinical entity from lymphedema that requires different treatment.
Lipedema is described as a progressive disease that can advance to lipolymphedema (Stage IV, with dorsal foot edema and positive Stemmer sign) and lead to immobility and significant decrease in quality of life.
Lymphoscintigraphy revealed abnormalities in 47% of lipedema patients across all clinical stages (including stage 1), with low-to-moderate grade lymphatic dysfunction predominating and no severe cases, suggesting subcutaneous lymphatic impairment coexists with lipedema but does not necessarily represent progression to frank lymphedema.
Both reported lipedema cases presented with bilateral varicose veins alongside characteristic disproportionate subcutaneous fat distribution, consistent with a described association between lipedema and varicose veins in the literature.
Evidence certainty: very low (GRADE) · 1 source(s)
A National Inpatient Sample analysis assessed the association between lymphedema/lipedema and venous thromboembolism in hospitalized obese women, adjusting for obesity and comorbidities.
In a survey of 209 German women with lipedema who underwent liposuction, hypothyroidism was present in 35.9% of participants, a frequency described as far beyond the average prevalence in the general German population.
In a cohort of 1803 lipedema patients in Spain, thyroid disorders were reported as a common comorbidity alongside other inflammatory and connective tissue conditions.
In a Brazilian cross-sectional screening study, hypothyroidism was common in women with lipedema (crude prevalence 19.4%) but was NOT an independent factor associated with lipedema on multivariate analysis (p=0.141) — the raw co-occurrence may reflect confounding (e.g. by obesity) rather than a true independent association.
This systematic review reports lipedema prevalence estimates of 11% in women (Földi), 15% of patients in a lymphology clinic (Herpertz), and 18.8% of 843 patients with lower-limb enlargement, occurring almost exclusively in women, with positive family history in 16–64% of cases.
This case report of a 53-year-old male with lipedema notes that lipedema is less frequent in men than in women, that obesity is the principal aggravating factor in both sexes, and that the authors' case series detects lymphedema by multi-segment bioimpedance in 50% of individuals with lipedema and BMI above 30 kg/m2.
Evidence certainty: very low (GRADE) · 1 source(s)
This case report cites epidemiological data estimating lipedema prevalence at approximately 11% of the female population, predominantly affecting women, and reports a UK study finding 93% of patients with lipedema signs/symptoms were unrecognized by their physicians; it also describes lipedema persisting in a woman with low BMI (15 kg/m²), demonstrating it is not exclusive to overweight/obese women.
Evidence certainty: very low (GRADE) · 1 source(s)
In a Saudi cross-sectional study of 115 patients with lower-limb edema, lipedema was clinically confirmed in 71%, affected only women with mean age 38.6 years and mean BMI 30.5, with disease onset typically at ages 20-39, perceived triggers being puberty (49%), pregnancy (22%), and massive weight loss (22%), a positive family history in 46% (predominantly mothers and sisters), and 77% being previously undiagnosed.
Lipedema is a chronic disorder presenting almost exclusively in women, typically beginning during periods of hormonal change such as puberty, childbirth, or menopause, with familial aggregation suggesting an autosomal dominant inheritance pattern and an estimated prevalence of 11–15% of adult women.
This systematic review of lipedema pathology notes that lipedema is a symmetrically localized, painful hypertrophy of subcutaneous adipose tissue in the extremities that almost exclusively affects females.
In a review citing a prior study of 160 lipedema patients, joint hypermobility was reported in over 50% of patients, and hypermobility associated with lipedema was noted as a risk factor for joint disease and aortic stiffness.
An American consensus standard-of-care guideline reports that joint hypermobility occurs in approximately 50% of women with lipedema, consistent with hypermobile Ehlers-Danlos syndrome (hEDS), listed as a comorbidity (GRADE 1.9 [A]).
Evidence certainty: very low (GRADE) · 1 source(s)
In lipedema patients, pain prevalence and von Frey cutaneous hypersensitivity increased with disease stage (60-100% leg pain across stages, painDETECT >19 only in Stage 3), with reduced dermal Tuj-1+ neuronal density in abdomen and elevated CGRP/NGF in Stage 3 tissues suggesting peripheral neuropathic pain and neurogenic inflammation, independent of BMI.
In a case series of five male lipedema patients, the one patient who underwent HLA typing was positive for both HLA-DQ2 and HLA-DQ8, and the authors cite prior data reporting HLA-DQ2 in 47.4% and HLA-DQ8 in 22.2% of women with lipedema; gluten-free dietary intervention was applied based on this positivity.
Evidence certainty: very low (GRADE) · 1 source(s) · 1 by Amato
This integrative theoretical perspective hypothesizes that gynoid subcutaneous fat is an evolutionarily adaptive energy reserve that confers metabolic and longevity advantages to women (citing ~7 years greater female lifespan) compared to visceral male fat, while framing lipedema as a maladaptive activation of this ancestral storage mechanism by chronic inflammatory triggers.
Evidence certainty: very low (GRADE) · 1 source(s) · 1 by Amato
In a study of women with lipedema (mean BMI 28.9) versus controls, lipedema patients showed a favorable plasma lipid profile (HDL 1.65 vs 1.04 mmol/L, p<0.0001; lower LDL:HDL and triglyceride:HDL ratios) and preserved metabolic indices (no difference in fasting glucose, insulin, or HOMA-IR), despite stage-dependent adipocyte hypertrophy, interstitial fibrosis, and inflammatory changes in affected thigh subcutaneous adipose tissue.
In a survey of 209 lipedema patients, symptom onset clustered in adolescence (mean age 16±9 years, 32.5% at ages 14-18), family history was common (affected grandmothers 35.4%, mothers 29.7%, aunts 23.0%), and 30.5% of premenopausal patients had sex-hormone imbalances, consistent with hormonal and hereditary contributions to lipedema onset.
This critical review proposes an integrative pathomechanism in which lipedema is an estrogen-regulated polygenetic disease, citing up to 60% of cases suggesting autosomal dominant inheritance with incomplete penetrance (Child et al., 330 relatives) and manifestation paralleling feminine hormonal changes, alongside estrogen receptor differences (decreased ERα, increased ERβ in the gluteal region) and animal models (PROX1+/-, VEGFR-3 mutants).
Evidence certainty: very low (GRADE) · 1 source(s)
A case report of idiopathic lipedema in a 62-year-old male—only the third such male case reported worldwide—notes that two of the three known male cases had associated hormonal alterations (alcoholic cirrhosis; type 1 diabetes plus alcohol abuse), and the near-exclusive female predominance is cited as suggesting a hormonal role in pathogenesis.
Evidence certainty: very low (GRADE) · 1 source(s)
This systematic review reports familial incidence of lipedema in 15% of first-degree female relatives consistent with X-linked dominant or autosomal dominant inheritance with incomplete penetrance, identifies an AKR1C1 missense variant (a gene involved in progesterone metabolism) as the first mutated gene in a family with primary non-syndromic lipedema, and notes hormonal/progesterone-pathway involvement.
Evidence certainty: very low (GRADE) · 1 source(s)
In 191 women with lower-limb lipedema (stages 1–3), a standardized two-stage lymph-sparing VASER ultrasound-assisted liposuction protocol reduced mean total limb circumference by 6.40 cm and mean VAS symptom score from 6.04 to 3.17 (p<0.001), with 89.8% patient satisfaction and complications including seroma (5.75%), skin necrosis (2.09%), and transfusion (3.14-4.18%).
In a case series of 126 lipedema patients (stages I–III) treated with selective combined liposuction (PAL with microcannulas plus VASER on proximal thighs), VAS scores significantly decreased for pain (6.4→2.7), heaviness (7.9→2.9), edema (5.0→1.6), and mobility limitation (5.0→1.6) at 6 months (all p<0.001), with 89% reporting pain improvement and BMI falling from 27.0 to 25.2 kg/m².
In a 60-patient single-centre prospective cohort with stage I-II lipedema, tumescent liposuction produced large symptom improvements (effect sizes d=1.04-2.18 for spontaneous pain, pressure sensitivity, edema, bruising, movement restriction, cosmetic impairment and quality of life) that persisted at 12 years post-operatively with no clinically relevant deterioration, and 27% of patients no longer required any conservative therapy.
In an 8-week RCT of 70 females with lipedema and obesity, a 1200 kcal/d low-carbohydrate diet produced greater fat mass loss (-7.0 vs -5.1 kg) and significant within-group reductions in hsCRP, TNF-α and MIP-1β versus a low-fat diet, but no between-group differences in cytokines or fibrosis markers were found, and changes in pain were not associated with changes in inflammatory markers or ketosis.
In a 10-year retrospective before-and-after study, lymph-sparing multistage liposuction (median 3 sessions, mean total 17,887 ml aspirated) produced durable improvements, with a median 37.5% reduction in conservative-therapy (CDT) score, 25.5% of patients discontinuing all conservative treatment, and significant VAS symptom reductions; outcomes were better in earlier stages (I+II) and in patients aged <41 years with BMI ≤35 kg/m².
This systematic review (1995-2011) reports that lipedema management consists of conservative complex decongestive therapy (CDT) — achieving up to ~10% leg circumference reduction and reduced capillary fragility (13.95 to 8.78 petechiae, P<0.001) — and tumescent liposuction, with early diagnosis and treatment recommended to prevent functional and cosmetic complications, though no clinical guideline or Cochrane recommendation existed as of 2012.
This narrative review recommends combined conservative therapy (manual or intermittent pneumatic lymphatic drainage, compression bandages and garments, and physiotherapy) with surgical liposuction as a more recent option, plus early recognition, specialized treatment, and regular follow-up to prevent progression.
Evidence certainty: very low (GRADE) · 1 source(s)
A narrative review proposes the very-low-calorie ketogenic diet (VLCKD) as a nutritional therapy for lipedema, citing anti-inflammatory effects; reported cases include a 6-month ketogenic diet (Cannataro 2021) yielding 41 kg total weight loss, reduced affected-limb circumferences (e.g., arm -10.5 to -11.5 cm), HOMA-IR reduction of 54%, and CRP reduction of 67%, and the LIPODIET trial (n=9) showing -4.5% weight loss and a 50% VAS pain reduction at 7 weeks that returned to baseline after diet cessation, while noting conventional decongestive therapy reduces tissue volume only 5-10%.
Evidence certainty: very low (GRADE) · 1 source(s)
This systematic review describes lipedema diagnostic criteria distinguishing it from venous and lymphatic disease (negative Stemmer sign, foot-sparing 'cuffing' sign) and reports a microangiopathy with increased capillary permeability, plasma VEGF approximately 4-fold above normal, and capillary fragility (13.95 petechiae pre-CDT reduced to 8.78 post-CDT, P<0.001), but does not directly quantify an association between lipedema and varicose veins.
In a cross-sectional study of 43 Czech women with lipedema, 50.9% had moderate-to-severe depressive symptoms (PHQ-9 >=10) and WHOQOL-BREF scores were low across domains (psychological 46.3, physical 50.8), with the psychological domain most affected; specific physical symptoms (shortness of breath, muscle stiffness, appetite problems, fatigue, numbness) were significantly associated with depression severity.
In a cross-sectional study of 354 women with lipedema, 35% met FMS criteria, and those with comorbid FMS had significantly higher anxiety (13.11 vs 9.87) and depression (10.23 vs 8.26) scores and lower SF-12 physical (35.37 vs 42.55) and mental (35.27 vs 40.38) quality-of-life scores (all p<0.001).
In a study comparing lipedema patients with population controls matched for sex, age and BMI, lipedema patients reported worse self-rated general health, higher rates of self-reported depression (43.6% vs 18.5%, p=0.001) with PHQ-8 depressive symptoms in 89.7% versus 39.3% of controls, more severe pain and pain-related disability, fewer close social contacts, and a strong positive correlation between pain severity and depressive symptoms (rho=0.612, p<0.001).
In a survey of 98 Polish women with lipedema, all WHOQOL-BREF domains scored below general-population values (physical health 45.4, psychological 46.3, social relationships 50.4, environment 49.6 on 0-100), 59.2% had PHQ-9 scores >=10 indicating possible depression (mean PHQ-9 12.2), and core lipedema symptoms (Factor 1: leg heaviness, joint/tissue/muscle pain, swelling, stiffness) were the only significant predictor of worse quality of life (beta=-0.345, p=0.004, model explaining 23.5% of variance).
In this scoping review, lipedema patients showed reduced quality of life (EQ-5D-3L 66.1 vs 85 in the Dutch population; WHOQOL-BREF physical/mental domains below midpoint), depression prevalence of 22.7%-42%, 51.1% with mental disorders, and QoL strongly correlated with depression severity (r=-0.75).
Evidence certainty: very low (GRADE) · 2 source(s)
In an observational study of 26 females with lipedema versus healthy controls, lipedema patients showed markedly higher emotion regulation difficulties (DERS total 135.69±13.12 vs 53.00±9.03) and anxiety (HAM-A 27.62±8.98 vs 4.96±2.51), with all group differences remaining significant after adjusting for BMI via ANCOVA (DERS total F(1,49)=582.95, p<0.001; HAM-A F(1,49)=123.10, p<0.001).
In 329 women with lipedema, lower quality of life (WHOQOL-BREF) was independently predicted by higher depression (PHQ-9 β=-0.36), higher appearance-related distress (DAS-24 β=-0.29), lower mobility (β=0.27) and higher symptom severity, with the final regression model explaining 73% of QoL variance and mean PHQ-9 of 11.87 indicating minor depression.
In a cross-sectional survey of 245 women with lipedema, health-related stigma was significantly higher than in an age-matched general female population (Distress 49.5 vs 17.1–28.7; 65% with moderate/severe distress) and correlated negatively with all RAND-36 quality-of-life domains (strongest for social functioning r=−0.54 and emotional well-being r=−0.50), while greater perceived social support correlated positively with HRQoL.
In a cross-sectional study of 37 women with lipedema versus 36 with lymphedema, lipedema patients showed moderate depression (PHQ-9 mean 10.4) and impaired global quality of life (LYMQOL-Leg 5.47) comparable to lymphedema patients, while lymphedema patients had worse functional status and life satisfaction; in lipedema, longer disease duration correlated with PHQ-9 (r=-0.415, p=0.028) and BMI correlated with functional impairment.
In a cross-sectional cohort of 40 lipedema patients, 87.5% showed severe/high depression risk (mean HAM-D 25.39) and 92.5% showed severe/high anxiety risk (mean HAM-A 23.45), with serum vitamin D inversely correlated with depression (adjusted r=-0.580, p<0.001) and anxiety (adjusted r=-0.489, p=0.002), and BMI positively correlated with both depression (r=0.560) and anxiety (r=0.511).
Compared with overweight/obese women, women with lipedema showed greater disability (WHO-DAS II domains for mobility, household activities, and social participation remained significantly worse after robust BMI adjustment, e.g. social participation Z=3.15, p=0.002; days with difficulties Z=4.13, p<0.001), but showed NO significant differences in depression (BDI-II median 11 vs 8, p=0.130; HADS-D p=0.474) or anxiety (HADS-A 9.16 vs 8.10, p=0.162), before or after BMI adjustment.
In 44 women with lipedema, median total SF-36 quality of life was 57.4/100 (lowest domains: general health 35, pain 47.5, social functioning 50, energy/fatigue 45), below historical healthy Polish population (61.6) and a prior lipedema cohort (59.3), and SF-36 scores did not differ by BMI or WHtR strata.
In a case report of lipedema initially misdiagnosed as lymphedema, the patient was treated with a complex decongestive therapy program, though the article notes that whether such treatments reduce swelling is debatable.
Evidence certainty: very low (GRADE) · 1 source(s)
In 15 patients with lipedema and secondary lymphedema, complete decongestive therapy plus pneumatic compression (mean 28.2 days) significantly reduced lower-limb volume (left: 15,958→15,110 mL, p=0.011; right: 16,132→14,779 mL, p=0.001) and circumference at most measurement points, though peri-patellar circumference did not respond.
This review identifies complete decongestive therapy (manual lymphatic drainage plus compression garments) as the gold-standard conservative treatment for lipedema, and reports that compression therapy, exercise, and pneumatic compression reduce pain and edema and improve patient-reported outcomes.
This review of surgical lymphology describes lymph-sparing liposuction (AMLD/Lymphological Liposculpture) for lipohyperplasia dolorosa as eliminating intractable pain and reducing limb circumference while obviating the need for lifelong complete decongestive therapy (CDT/TDC), framing surgery as an option when conservative measures fail.
Evidence certainty: very low (GRADE) · 1 source(s)
In this review, a 24-patient study found that none of the patients treated with CDT alone achieved pain reduction (versus 15/18 with liposuction), and the article concludes conservative treatments have limited and questionable efficacy; only intermittent pneumatic compression combined with MLD and bandaging in 38 patients showed significant pain reduction over 5 days.
Evidence certainty: very low (GRADE) · 1 source(s)
In a proof-of-principle study of 5 women with Stage 1-2 lipedema, a 6-week multimodal physical therapy program (manual lymphatic drainage, myofascial release, negative-pressure device, exercise, compression, education) reduced pain VAS from 4.6 to 0.0 (p=0.005), improved PSFS function by 3.8 points (p<0.001), and lowered skin and subcutaneous sodium on MRI (-9% p=0.059; -8% p=0.12) with QoL improvement in 4/5 participants.
In an 8-week RCT of 24 women with lipedema, class-2 flat-knit compression leggings combined with exercise significantly improved SF-36 Physical Functioning and Energy/Fatigue and reduced symptom severity (heaviness 7.5→4.5/10, swelling 7.5→4.5/10, disproportion 6.5→3.5/10), with pain decreasing in the compression group (5→4/10, non-significant) while limb volume showed no significant change in either group.
A simplified 9-item self-applied screening questionnaire (derived from the validated QuASiL) based on clinical diagnostic criteria (post-pubertal women, bilateral symmetric fat deposit below the hip sparing feet, negative Stemmer and Godet signs, pain on palpation, spontaneous bruising) achieved diagnostic discrimination of AUC=0.912 for an individual 7-question predictive model and AUC=0.8615 for a total-score model against expert clinical diagnosis in 109 women (59 with lipedema, 50 without), with the item 'feeling something wrong in the legs' being most discriminative (OR=4.328).
In a prospective cohort of 83 women diagnosed with lipedema using clinical criteria, lipedema was classified by clinical stage (most often stage 1, 39.8%) and type (most often type III, hips to ankles, 74.7%), and lymphoscintigraphic abnormality grade showed no significant association with clinical stage (p=0.142), type (p=0.505), Stemmer's sign (p=0.506), age, or BMI.
In a prospective cohort of 138 lipedema and 111 lymphedema patients, a CART algorithm using three clinical variables—bruising, body disproportion, and non-swollen feet (cuffing sign)—classified patients with 100% accuracy; lipedema was characterized by symmetry (100%), spared feet (93.5%), pain (92%), bruising (90.6%), telangiectasias (89.9%), and family history (84.7%), and staged 1-4 (stage I 37.7%, II 34.8%, III 22.5%, IV 5.1%).
Bioimpedance spectroscopy of regional tissue fluid distinguished lipedema from Dercum's disease (lower leg/arm R0 ratio in lipedema, p<0.001) and detected stage 1 lipedema versus matched controls (leg/arm ratio R0 p=0.01, R1 p=0.007), with leg extracellular water increasing across lipedema stages (p=0.03), proposing BIS as an objective adjunct biomarker for diagnosis and staging.
This systematic review of molecular and cellular lipedema studies argues that the current staging system based on Wold (1951) is insufficient for the disease's clinical heterogeneity and proposes its revision to incorporate comorbidities (obesity, lymphedema), pre-surgical weight, and family history.
Evidence certainty: very low (GRADE) · 1 source(s)
The S2k lipedema guideline defines lipedema as painful, disproportionate, symmetrical adipose distribution occurring almost exclusively in women, and states that diagnosis is clinical, requiring disproportion plus concomitant symptoms (pain), while morphological staging should NOT be used as a measure of severity, the 'nodular' criterion should not be used for diagnosis, and no instrument (duplex, ultrasound, MRI, lymphoscintigraphy, laboratory tests) can confirm lipedema (they serve only for differential diagnosis).
Evidence certainty: very low (GRADE) · 1 source(s)
This systematic review describes lipedema diagnosis as primarily clinical and outlines a 3-stage clinical staging system (Stage I normal skin with small palpable nodules; Stage II irregular surface with liposclerosis; Stage III lobular deformation with peau d'orange) plus Schingale's 5-type classification (I hips/thighs, II to knees, III to ankles, IV arms+legs, V lipo-lymphedema), with key differential signs (negative Stemmer, foot dorsum sparing) and noncontrast CT reported at 95% sensitivity and 100% specificity.
A review of 13 tools used to quantify lipedema limbs (8 imaging, 5 clinical measurement) found highly heterogeneous and poorly documented protocols — e.g., tape measurement used inconsistent anatomical sites and volume formulas, and ultrasound studies omitted machine settings — with clinimetric reliability reported in only a minority of studies, limiting reproducibility and cross-study comparison.
In a cohort of 83 women with clinically diagnosed lipedema, lymphoscintigraphy showed lymphatic alterations in 47% (mostly low or low-moderate grade, none severe), with the degree of involvement unrelated to age, Stemmer's sign, BMI, clinical stage, or lipedema type, indicating that abnormal findings do not exclude lipedema while normal findings would support the diagnosis.
In 50 lipedema patients versus 50 controls, ICG lymphography and lymphoscintigraphy revealed slower superficial lymph flow (ICG reached upper calf in 8% vs 56%, p<0.0001), more numerous and dilated/tortuous lymphatic vessels, higher fluorescence intensity, higher skin water concentration in the feet (p=0.000189), and increased subcutaneous tissue stiffness, supporting their utility in diagnosing lipedema.
In a DXA body composition study, the leg fat mass/total fat mass index distinguished lipedema patients from healthy controls with AUC=0.90 (sensitivity 0.95, specificity 0.73 at cutoff 0.383) across all BMI strata, with elevated leg fat proportion (0.451 vs 0.354) and inverted trunk/legs ratio (0.960 vs 1.502), while appendicular lean mass and total bone density did not differ.
A deep learning MRI pipeline using 3D DIXON MR-lymphangiography achieved standardized quantification of subcutaneous (Dice 0.989) and subfascial (Dice 0.994) tissue volumes in the lower limbs and demonstrated differentiation of patients without edema versus lipedema versus asymmetric lymphedema based on volume, distribution, and symmetry.
On non-contrast MR lymphography of 44 lower extremities, pure lipedema showed homogeneous subcutaneous fat without epifascial fluid (0%) while lipolymphedema showed epifascial fluid collections (100%, p<.001) and dilated peripheral lymphatics (90.9% vs 18.2%, p=.001), with no honeycomb pattern and normal iliac lymphatic trunks in both groups.
Noninvasive 3T MR lymphangiography revealed distinct topographic patterns of subcutaneous adipose tissue hyperintensity (extravascular and vascular) that distinguished lipedema, lipedema-with-lymphedema, and cancer-related lymphedema from BMI-matched controls, with cancer lymphedema showing more frequent dilated vascular patterns (OR=12.27) and diffuse hyperintensity observed only in disease groups, supporting imaging-based differentiation.
Near-infrared fluorescence lymphatic imaging (NIRF-LI) of 20 individuals with Stage I-II lipedema showed dilated lymphatic vessels (94-100% of legs), increased lymphatic propulsion rate (1.4 events/min vs 0.9 in controls, p=0.0102/0.0258), and complete ABSENCE of dermal backflow, in contrast to lymphedema; foot fat-sparing attenuation was seen in ~81% of legs, and absence of dermal backflow correctly excluded lymphedema in a previously misdiagnosed patient.
In this systematic review, non-contrast CT showed 95% sensitivity and 100% specificity for diagnosing lipedema (Monnin-Delhom), and imaging plus clinical signs (sparing of the foot dorsum, negative Stemmer sign) differentiate lipedema from lymphedema.
In a systematic review of 7 studies (51 patients) with lipedema and obesity undergoing bariatric/metabolic surgery, mean total weight loss was 33.9% but only 1 study (n=31) reported significant thigh volume reduction, while the remaining studies showed persistent or worsened lower-limb disproportionality and no improvement in pain.
In a case series of 13 patients who lost an average of >50 kg (BMI from 50 to 32 kg/m²) after bariatric surgery, characteristic lipedema limb pain did not improve (VAS 7.3 pre vs 7.9 post, p=0.28) and extremity fat persisted, indicating substantial weight loss did not reduce lipedema fat or symptoms.
In patients with lipedema (mean baseline BMI 48.5), bariatric surgery (sleeve gastrectomy or RYGB) reduced adjusted thigh volume by 33.4% at first follow-up, comparable to the 37.0% reduction in lymphedema controls (p>0.999), with greater reduction in those with BMI ≥50 (44.4% vs 33.2% for BMI 35-<50) and reduction correlating with excess BMI loss.
This review reports that bariatric surgery is not effective for lipedema, as lipedematous fat does not respond to caloric restriction or malabsorptive procedures, with weight loss occurring in unaffected areas instead.
Evidence certainty: very low (GRADE) · 2 source(s)
In two case reports of patients with coexisting obesity and lipedema, bariatric surgery produced major weight loss (64 kg and 73.9 kg) but thigh and calf circumferences remained virtually unchanged or even increased, and both patients retained limb pain and required long-term compression therapy, indicating lipedematous tissue was refractory to surgical weight loss.
Evidence certainty: very low (GRADE) · 1 source(s)
In a review and chart analysis of 46 women with lipedema, lifestyle changes and weight loss did not reduce lipedema fat, which remained refractory to diet and exercise.
In two patients after bariatric surgery (gastric bypass with 62% excess weight loss; sleeve gastrectomy with 49% excess weight loss), lipedematous fat of the lower limbs persisted despite substantial weight loss, demonstrating resistance of lipedema fat to caloric deficit.
Evidence certainty: very low (GRADE) · 1 source(s)
In women with obesity and lipedema, moderate diet-induced weight loss (~9%) reduced lower-body (leg/thigh) adipose mass with relative reductions similar to abdominal fat and improved insulin sensitivity, refuting the notion that lipedema fat is resistant to weight loss, though inflammation and fibrosis markers did not change.
Family-based exome sequencing of 31 individuals from 9 lipedema families identified candidate variants in 469 genes with no single gene shared across all families, supporting genetic heterogeneity rather than a Mendelian single-gene cause, with gene ontology enrichment in vasopressin receptor activity (AVPR1A, AVPR2), microfibril binding (FBN, ELN, LTBP), and patched binding (PTCH1/2, Hedgehog pathway).
This systematic review reports specific genetic findings in lipedema including an AKR1C1 missense variant (Michelini 2020) associated with reduced progesterone clearance and increased adipogenesis, a familial Pit1 mutation causing GH and testosterone deficiency (Bano 2010), and upregulation of ZNF423 and CAV1 dysfunction, supporting a possible genetic susceptibility component.
A systematic review of lipedema pathology reported that, despite growing histological and molecular research, the aetiology remains largely uncertain; it noted differential gene expression in lipedema adipose-derived stem cells (3429 genes, including cell-cycle genes Bub1, CDC20, BIRC5 per Ishaq) but did not identify specific inherited variants or defined inheritance patterns.
In a series of 67 probands, 14.9% had at least one affected first-degree relative (all affected relatives female), X-chromosome linkage analysis in the largest family excluded X-linked dominant inheritance (lod scores < -2) favoring autosomal dominant inheritance with sex limitation, and onset at puberty in 55% of probands plus near-exclusive female occurrence suggested estrogen-dependent expression.
This narrative review reports genetic evidence (305 candidate genes via next-generation sequencing in 162 patients; 18 GWAS risk loci including VEGFA and GRB14-COBLL1 validated in UK Biobank; monogenic AKR1C1 and PIT1 mutations affecting progesterone and growth-hormone/prolactin pathways) supporting both hereditary and hormonal influences on lipedema onset.
Evidence certainty: very low (GRADE) · 1 source(s)
This integrative review proposes that menopause acts as a critical inflection point in lipedema progression via estrogen receptor imbalance (downregulated ERα and upregulated ERβ in affected tissue), increased local intracrine estradiol production through elevated aromatase (CYP19A1) and 17β-HSD1 with deficient 17β-HSD2, and progesterone resistance, reframing lipedema as an estrogen-dependent disorder.
Evidence certainty: very low (GRADE) · 1 source(s)
Gaps: Hypothesis/model paper (narrative review), not primary evidence; light-review venue. Treat as mechanistic context, not as establishing the association.
This comparative narrative review reports that lipedema is almost exclusively found in women and typically begins during periods of hormonal change (puberty, pregnancy, menopause), and notes heritability/genetic markers as part of its genetics domain.
Evidence certainty: very low (GRADE) · 1 source(s)
This multidisciplinary review reports that lipedema shows familial history in 30-89% of cases with polygenic GWAS findings (loci in CPE, ZNF25, ZNF33A linked to estrogen biology, plus VEGFA and GRB14-COBLL1, and an AKR1C1 missense variant) and that onset or worsening clusters at hormonal transitions—puberty (15.7-67.3%), pregnancy/lactation (9.5-63.1%), and menopause (1.9-21%)—with estradiol altering ERα/ERβ and PPAR-γ2 expression in lipedema-derived adipose stem cells.
Evidence certainty: very low (GRADE) · 1 source(s)
In a rigorously defined UK lipedema cohort (n=130), onset was frequently associated with hormonal changes (puberty, pregnancy, menopause), and the first dedicated GWAS identified a suggestive genetic locus (rs1409440, OR_meta 2.01, P_meta 4×10⁻⁶) upstream of LHFPL6, replicated in an independent 100,000 Genomes cohort.
This review proposes that dysregulated estrogen signaling in adipose tissue—via an increased ERα/ERβ ratio in gluteofemoral adipocytes or excessive local paracrine estrogen production by adipocyte steroidogenic enzymes—drives the excessive subcutaneous fat accumulation in lipedema, and cites whole-exome sequencing linking lipedema to variants in sex hormone genes, with onset coinciding with hormonal fluctuation periods such as puberty, pregnancy, and menopause.
Evidence certainty: very low (GRADE) · 1 source(s)
A GWAS of an inferred lipedema phenotype in UK Biobank women identified 18 genome-wide significant loci (SNP heritability ~5.13%), including RSPO3 (OR=1.24), GRB14-COBLL1, VEGFA, and ADAMTS9 (some replicated in an independent clinically-diagnosed lipedema cohort), with genetic correlations to body fat, leptin levels, and age at menopause.
This narrative review reports that lipedema onset is associated with periods of hormonal fluctuation (puberty, pregnancy, menopause) and describes estrogen-dependent mechanisms (increased aromatase CYP19A1, estrogen-induced ZNF423 hyperproliferation), alongside a proposed female-preferential autosomal dominant inheritance pattern.
Evidence certainty: very low (GRADE) · 1 source(s)
This review reports that lipedema develops or worsens during hormonal-change windows (puberty, pregnancy, menopause, oral contraceptives), with ~20% of cases identified at menopause and ~67% of patients reporting symptom exacerbation at its onset, and proposes an estrogen-receptor imbalance (decreased ERalpha/increased ERbeta) in affected adipose tissue as a central mechanism.
Evidence certainty: very low (GRADE) · 1 source(s)
This review proposes AKR1C enzymes (AKR1C1-4) as a central biological pathway linking rare familial mutations (e.g., AKR1C1 L213Q segregating with lipedema across 3 generations, AKR1C2 Ser320PheTer2) and common regulatory polymorphisms (rs28571848, rs34477787) to lipedema through altered steroid hormone metabolism in gluteofemoral subcutaneous adipose tissue, with environmental endocrine disruptors and hormones converging on the same hereditary pathway.
This review synthesizes evidence that estrogen and its receptors (ERα, ERβ, GPER) influence lipedema pathogenesis, noting disease onset/aggravation during hormonal-fluctuation windows (puberty, pregnancy, menopause) and that altered ER expression in gluteofemoral subcutaneous adipose tissue (reduced ERα, increased ERβ) parallels the regional fat accumulation characteristic of lipedema, affecting ~11% of women.
Evidence certainty: very low (GRADE) · 1 source(s)
This narrative review describes lipedema as having a hereditary component with autosomal dominant familial inheritance, and notes shared and distinct genetic markers between lipedema and lymphedema.
Evidence certainty: very low (GRADE) · 1 source(s)
This review reports lipedema as polygenic with familial history in 30-89% of cases, citing a 2022 GWAS (130 carriers) identifying 6 regions (CPE, ZNF25, ZNF33A linked to estrogen biology), a UK Biobank study (24,450 women) finding 18 loci replicating VEGFA and GRB14-COBLL1, a partial loss-of-function missense variant in AKR1C1 in a non-syndromic lipedema family, and a multigene panel of 305 loci finding 17 probable deleterious lesions in 21/162 participants, with no single causal gene and no overlap with primary lymphedema or lipodystrophies.
A GWAS of a UK lipedema cohort (n=130) identified a suggestive association (not genome-wide significant) at SNP rs1409440 (OR_meta 2.01; P_meta 4×10⁻⁶) located upstream of LHFPL6, a gene involved in lipoma formation, with additional support from an independent 100,000 Genomes replication cohort.
This systematic review reports that lipedema most likely follows autosomal dominant inheritance with incomplete penetrance and sex limitation (positive family history in up to 64% of women), identifies no confirmed gene for primary non-syndromic lipedema, and catalogs syndromic associations (POU1F1A c.196C>T p.Pro24Leu; NSD1 p.Cys2175Ser/Sotos; 7q11.23 deletion/Williams-Beuren with ELN, FZD9, MLXIPL; ABCC6/PXE; ALDH18A1/cutis laxa III) plus 17 GWAS/animal-model candidate genes (e.g., LYPLAL1, TBX15, HOXC13, RSPO3, VEGFA, PROX1, VEGFR3, PRDM16).
Evidence certainty: very low (GRADE) · 1 source(s)
This narrative review reports that lipedema follows a female-preferential autosomal dominant inheritance pattern and is associated with altered expression of specific genes including CCND1, ZNF423, CYP19A1 (aromatase), COL6A3, and MMP14, while noting that genetic studies remain underpowered.
Evidence certainty: very low (GRADE) · 1 source(s)
This review identifies specific lipedema-associated variants in AKR1C genes, including the familial AKR1C1 p.Leu213Gln (L213Q) mutation segregating across three generations and reducing catalytic efficiency ~50%, the gain-of-function AKR1C2 Ser320PheTer2 mutation, AKR1C2 overexpression in 24% (5/21) of patients without coding mutations, and regulatory SNPs rs28571848 (glucocorticoid receptor site) and rs34477787 (RORα site) that increase AKR1C2/AKR1C3 expression and truncal fat mass independent of BMI.
Targeted NGS and molecular dynamics simulations identified three missense AKR1C1 variants (L54V, L54F, N280K) in lipedema patients that disrupt substrate or cofactor (NADP+) binding, and screening of gnomAD identified 8 rare AKR1C1 polymorphisms as potentially pathogenic, extending AKR1C1 as a candidate gene for autosomal dominant non-syndromic lipedema.
In a RCT of 33 women with severe lipedema, CDT (manual lymphatic drainage plus low-elasticity multilayer bandaging) combined with exercise was superior to IPCT-plus-exercise and exercise-alone, reducing limb volume (Δ -1,153 mL right, -1,198 mL left; group p=0.017 and p<0.001), pain on VAS (7.73→3.09, ~60% reduction; group p=0.045), and improving SF-36 physical functioning (31.36→53.18; group p=0.040).
In an observational study of 293 patients receiving a modified Complete Decongestive Therapy protocol (Godoy Method) in the immediate postoperative period after lipedema liposuction, the number of physiotherapy sessions was associated with significant pain reduction (mean VAS ≈7.04 pre-therapy to ≈3.98 immediately and ≈2.34 at 90 days, p=0.000), improved mobility (p=0.003), and fewer complications (p=0.007).
In a meta-analysis of 7 studies on liposuction for lipedema, approximately 51% of patients still required conservative therapy postoperatively, with one study (Witte) reporting manual lymphatic drainage use declining from 88.9% to 39.7% and compression from 95.2% to 31.7% at 21.5 months, but the analysis did not directly evaluate complete decongestive therapy as a primary intervention.
In a cross-sectional study of patients diagnosed with lipedema in Saudi Arabia, hypothyroidism was reported as a comorbidity in 16% of patients, though no adjusted analysis of the lipedema-thyroid association was performed.
In a meta-analysis comparing TTL, PAL, and WAL liposuction techniques for lipedema, all techniques produced significant improvements across all combined outcomes (pain MD=45.89, QoL MD=52.47, all P<0.00001) with an adjusted overall complication rate of 2.3% per procedure and 6.4% per patient, with hematoma the most frequent complication (8.4%) attributed to capillary fragility.
In a meta-analysis of 20 studies (1785 patients, mostly tumescent technique), liposuction for lipedema produced significant improvements in quality of life (SMD 2.48), pain (SMD 2.04, 72% reduction), and pressure sensitivity (SMD 2.20), with a low complication profile (seroma 0.82%, hematoma 0.71%, infection 0.59%) and zero mortality over ~15 months follow-up.
In a 10-year retrospective study of 106 lipedema patients undergoing multistage lymphatic-sparing liposuction (PAL/WAL), median CDT composite scores dropped 37.5% and pain VAS fell from 80 to 30 (p<0.0001), with 34.9% no longer needing compression garments, low complication rates (1.3% wound infection, 0.7% seroma), and better outcomes in younger patients with BMI ≤35 and earlier disease stage.
LIPLEG is a planned multicentre investigator-blinded RCT randomising 405 women with painful lipedema (2:1) to liposuction plus CDT versus CDT alone, with the primary endpoint being a ≥2-point pain reduction on the NRS at 12 months, but the article is a study protocol with no results yet (recruitment started December 2020; NCT04272827).
In 111 lipedema patients undergoing 334 low-volume micro-cannular liposuction sessions under exclusive tumescent anesthesia, pain dropped 72% (VAS 7.8 to 2.2), thigh circumference reduced 6±1.6 cm, mobility improved in 100%, and 16.4% no longer required complex decongestive therapy, with 1.2% serious adverse events and no fatalities over a median 2-year follow-up.
In a longitudinal study of 25 lipedema patients undergoing tumescent liposuction (mean 3 procedures, mean 9,914 mL removed), spontaneous pain VAS decreased from 7.2 to 4.3, quality-of-life VAS improved from 8.4 to 5.2, and CDT scores fell from 20.5 to 13.9 at ~37 months (all p<0.05), with only 1 erysipelas complication in 72 procedures (1.39%) and better sustained outcomes in stage II than stage III.
In an 8-week RCT of 13 females with obesity and lipedema, a 1,200 kcal/day low-carbohydrate diet (75 g/day carbohydrates) produced significant reductions in calf subcutaneous adipose tissue area, calf circumference, and pain not seen in the isoenergetic low-fat control group, while both diets reduced body weight, fat mass, and muscle area.
This hypothesis-generating review proposes a modified ketogenic diet (<20g carbohydrate/day) for lipedema across 7 target outcomes, rating evidence as 'strong' for weight/adipose tissue reduction, pain reduction, and quality-of-life improvement, and 'promising' for hormonal normalization, edema reduction, inflammation (BHB-mediated NLRP3 inhibition), and fibrosis; it cites a clinical observation that pain was significantly reduced after 7 weeks of KD and returned after 6 weeks of standard diet despite maintained weight loss, suggesting a weight-independent analgesic effect.
A systematic review reports that lipedema is a distinct clinical entity differentiable from lymphedema (negative Stemmer sign, no foot involvement, bilateral symmetry, spontaneous pain and bruising) and from obesity, supported by distinct histopathology (enlarged adipocytes, increased capillaries, macrophage infiltration, CD68+ cells, and Ki67+/CD34+ progenitor proliferation), and proposes a diagnostic algorithm.
Evidence certainty: very low (GRADE) · 1 source(s)
This review describes lipedema as a distinct fat disorder differentiated from obesity by adipose tissue resistant to diet/exercise and ineffective bariatric surgery, and from lymphedema by absence of foot involvement (cuff sign, negative Stemmer sign in early stages) and helical/corkscrew-shaped lymphatic vessels.
Evidence certainty: very low (GRADE) · 1 source(s)
In a chart review of 46 women with lipedema (mean BMI 35.3 kg/m²), lipedema fat was associated with notably lower rates of metabolic dysfunction than expected for obesity (diabetes 2%, dyslipidemia 11.7%), is not reduced by lifestyle change, and is frequently misdiagnosed as obesity or lymphedema, with distinct distribution types and clinical staging.
In a 3-year follow-up case report of a 53-year-old male, lipedema co-occurred with post-surgical right lower-limb lymphedema and progressed from subclinical to clinical systemic lymphedema detected by multi-segment bioimpedance, with the authors reporting that lymphedema is detected in 50% of individuals with lipedema and BMI over 30 kg/m2.
Evidence certainty: very low (GRADE) · 1 source(s)
In 258 women with clinically diagnosed lipedema, the prevalence of subclinical systemic lymphedema and clinical lower-limb lymphedema increased progressively with BMI (Group I <30: 16.3% subclinical, 6.1% clinical; Group II 30-40: 48.3% and 51.6%; Group III 40-50: 72.2% and 77.8%; p=0.0001), and lipedema patients could develop edema even at normal weight.
A practical guide distinguishes lipedema from lymphedema, obesity (adiposity), Dercum's disease, and lipomatoses, citing features such as bilateral symmetric proximal fat distribution, negative Stemmer sign, foot sparing, easy bruising, and resistance to diet/exercise and bariatric surgery, in contrast to lymphedema (positive Stemmer, pitting edema, foot involvement) and obesity.
Evidence certainty: very low (GRADE) · 1 source(s)
In a comparative lymphoscintigraphy study (15 women with lipedema vs 15 with primary lymphedema), inguinal lymph nodes were absent in 14/15 lymphedema cases but only 1/15 lipedema cases (p<0.001) and colloid half-life was longer in lymphedema (230±92 vs 121±36 min, p<0.01), and the Stemmer sign is positive in lymphedema but negative in lipedema, with the review describing lymphedema and lipedema as distinct entities and lipedema's fat distinct from obesity (weight loss reduces truncal but not limb fat).
Evidence certainty: very low (GRADE) · 1 source(s)
This review estimates lipedema affects approximately 1 in 9 adult women, occurs almost exclusively in women with bilateral symmetric limb adiposity sparing the feet, and notes 15-17% of patients treated for lymphedema have concomitant lipedema.
Evidence certainty: very low (GRADE) · 1 source(s)
In a Swedish national survey of women with lipedema, 69% reported symptom onset before age 30 but the most frequent age at diagnosis was 50-59 years (34.9%), with the most common subtype being combined type 3+4 (buttocks-ankles plus arms) in 58.7% of participants.
In a prospective cohort of 138 lipedema patients (median age 47.6 years), 85% reported a positive family history, 57% had symptom onset related to puberty (median onset age 14.8 years), and Type III (ankle-to-hip) involvement predominated at ~71%, with a median diagnostic delay exceeding 25 years.
Using 15 MHz cutaneous ultrasonography with computer-assisted (ImageJ) measurement of dermal echogenicity, lipedema was characterized by increased subcutaneous thickness and subcutaneous hypoechogenicity throughout the limb (subcutaneous echogenicity at calf ~60 vs 79 in lymphedema, p=0.005) and a preserved dermal:subcutaneous echogenicity ratio, distinguishing it from lymphedema which showed predominantly distal dermal thickening and dermal hypoechogenicity.
In a systematic review of objective lipedema assessment tools, two ultrasound studies documented anatomical measurement points (mid-thigh, mid-shin, supra-malleolar), and one (Amato 2021) proposed a diagnostic cut-off of pretibial subcutaneous thickness >11.8 mm, though no study reported machine frequency/gain or acquisition time, limiting reproducibility.
High-resolution ultrasound (10–13 MHz) measuring cutis-subcutis thickness, compressibility, and sonomorphology could not reliably differentiate lipedema from lipohypertrophy, obesity, or healthy controls (lipedema vs lipohypertrophy compressibility 22.2% vs 22.7%; blinded reviewer failed to classify entities), though it could distinguish lipedema from lymphedema (which shows cutaneous hypoechogenicity).
In a DXA body composition study comparing lipedema patients to controls, the article cites subcutaneous ultrasound as achieving an AUC of 0.91 for lipedema diagnosis (Amato et al. 2021), while reporting DXA's own leg FM/total FM index reached AUC=0.90 with sensitivity 0.95 and specificity 0.73.
High-resolution duplex sonography (11-12 MHz) measuring subcutis+cutis thickness 8 cm above the medial malleolus distinguished lipedema (~16 mm) from non-lipedema (11±2.8 mm) and at the medial knee (25.5 mm vs 14.7±5 mm), with proposed severity grading (12-15 mm mild, 15-20 mm moderate, >20 mm distinct, >30 mm marked) and a homogeneously hyperechogenic 'snow storm' subcutis without echo-free clefts differentiating lipedema from lymphedema.
Using a previously validated online screening questionnaire (cutoff ≥12 points, AUC 0.8615, specificity 0.88, sensitivity 0.46, PPV 0.767), a population-representative study estimated lipedema prevalence at 12.3% among Brazilian women aged 18-69, corresponding to roughly 8.8 million women with suggestive symptoms.
In non-obese lipedema patients, standardized QST (DFNS protocol) revealed selective alterations in only 2 of 13 parameters at the affected lateral thigh—elevated pressure pain (PPT, AUC 0.9075) and reduced vibration detection (VDT, AUC 0.8638)—and a combined PPT+VDT z-score score was proposed as a rapid diagnostic test for lipedema.
This editorial commenting on Crescenzi et al. (2023) emphasizes the lack of reliable lipedema biomarkers and highlights noncontrast 3T MR lymphangiography—which reveals subcutaneous adipose tissue edema and increased lymphatic load—as a promising imaging biomarker that could aid differential diagnosis between lipedema and obesity, while noting small sample sizes limit current evidence.
Evidence certainty: very low (GRADE) · 1 source(s)
This reply letter states that lipedema is frequently underdiagnosed and confused with obesity and lymphedema (worsened by phonetic similarity among 'lipedema', 'lipidemia', and 'lipemia'), and defends an ultrasound diagnostic cutoff incorporating dermal and subcutaneous thickness (mean subcutaneous thigh thickness 20.9 mm in lipedema vs 12.67 mm in controls).
Evidence certainty: very low (GRADE) · 1 source(s)
In a cross-sectional online survey, lipedema patients more frequently reported hypermobility (44% in adulthood, ~60% in childhood), joint pain, and multisystem symptoms than lymphedema patients, and the authors note lipedema remains underdiagnosed and should be reconceptualized as a systemic connective tissue disorder.
A systematic review of molecular and cellular lipedema research estimated worldwide prevalence at approximately 11% among women, noting this figure is inflated by underdiagnosis and acknowledged diagnostic limitations, but the review focused on molecular biology and did not evaluate screening tools.
Evidence certainty: very low (GRADE) · 1 source(s)
In a cohort of 83 women with clinically diagnosed lipedema, symptoms began at a mean age of 20.4 years but diagnosis occurred at a mean age of 46.5 years, indicating a mean diagnostic delay of 26.1 years, while lymphoscintigraphy showed lymphatic alterations in 47% of patients across all clinical stages.
This narrative review describes lipedema as a common but rarely diagnosed condition frequently confused with obesity, emphasizing that early recognition based on the diagnostic triad of spontaneous pain, pressure pain, and easy bruising is essential to prevent progression.
Evidence certainty: very low (GRADE) · 2 source(s)
A systematic review reported that lipedema is poorly recognized clinically—only 46.2% of 251 Vascular Society of Great Britain and Ireland consultants recognized it (Tiwari 2006)—and that it was absent from MeSH/EMBASE and ICD-WHO as of 2012, while non-contrast CT showed 95% sensitivity and 100% specificity and the spared foot dorsum (negative Stemmer sign) helps distinguish lipedema from lymphedema.
In a case-control study, carriers of the IL-6 rs1800795 G allele had a 5.92-fold higher risk of lipedema (OR=5.92, 95%CI 1.983–17.711, p<0.001), and DXA-derived body composition indices (reduced WHR 0.73 vs 0.79, higher lower-limb FM% 48.90% vs 42.55%) combined with genetic analysis were proposed as tools for differential diagnosis between lipedema, normal-weight obesity, and obesity.
In a prospective cohort of 138 lipedema and 111 lymphedema patients, a CART algorithm using only three clinical variables (bruising, body disproportion, and non-swollen/spared feet) classified lipedema versus lymphedema with 100% accuracy, and the median time from symptom onset to diagnosis was markedly longer in lipedema (25.5 years vs 12.1 years for lymphedema, p<0.0001).
In a comparative observational study, 39.6% (21/53) of lipedema patients met ACR 2016 criteria for fibromyalgia, and the comorbid lipedema+fibromyalgia subgroup had significantly higher pain (median VAS 60 vs 27 for lipedema alone, p<0.001) and worse SF-36 quality-of-life scores across all 8 domains.
In a comparative study, fibromyalgia prevalence was 10% in lipedema patients (versus 28% in Dercum's disease, P=0.0003) and migraines were reported in 7% of lipedema patients (versus 21% in Dercum's, P=0.005), with a mean pain score of 4±2.5 on a 0–10 scale among lipedema patients.
In a Swiss cohort of 381 lipedema patients, pain was reported by 87.9% (high pain BPI≥7 in 14.2%) and high fatigue (FSS≥4) in 56.1%, but rheumatic comorbidities and chronic-pain-specific conditions such as fibromyalgia were not separately quantified, and joint hypermobility (Beighton≥5) was present in only 4.2%.
In a cross-sectional online survey, lipedema patients reported higher frequencies of chronic joint pain (ankles 70%, cervical spine 66%, knees 56%) and multisystem symptoms than lymphedema patients, with 26% recalling frequent childhood limb/back pain versus 12.7% in lymphedema, though differences were not statistically tested.
In a retrospective cohort of lipedema patients undergoing multistage liposuction, 22.6% had a prior migraine diagnosis, of whom 66.7% reported reduced intensity and/or frequency of attacks postoperatively (p<0.0001).
In a survey of lipedema patients, all reported physical complaints including pain (88.3%, mean current NRS 4.2) and fibromyalgia was among the reported comorbidities (n=14), with comorbidities associated with significantly reduced quality of life.
In a case series of 189 women undergoing lipedema reduction surgery, reported comorbidities included joint hypermobility (50.5%), arthritis (29.1%), depression (22.8%), and migraine (8.4%), but fibromyalgia was not specifically reported and no adjusted analysis of pain-condition associations was performed.
This narrative review of lipedema morphology and pathophysiology states that lipedema leads to chronic pain, swelling, and other discomforts due to bilateral asymmetrical subcutaneous adipose tissue expansion, but it does not specifically examine an association with fibromyalgia or other defined chronic-pain conditions.
Evidence certainty: very low (GRADE) · 1 source(s)
Quantitative sensory testing in non-obese women with lipedema showed a 2-fold reduced pressure pain threshold and 2.5-fold increased vibration detection threshold selectively in the affected thigh (quadriceps/patella) but not the hand, with no central alterations, suggesting a peripheral pain mechanism via ECM stiffness and mechanoceptive amplification.
Evidence certainty: very low (GRADE) · 1 source(s)
In a cross-sectional comparison of 53 women with lipedema versus 55 with lifestyle-induced overweight/obesity, despite lower BMI the lipedema group showed more favorable metabolic profiles (lower TG, LDL-C, HbA1c, HOMA-IR, uric acid; higher HDL-C; insulin resistance 11.3% vs 34.5%, p=0.01), and PCA identified the fat-distribution component (more peripheral/limb fat vs abdominal, higher PC3) as the strongest predictor of better metabolic markers independent of total body weight.
In 360 Italian women with lipedema (a peripheral/gynoid fat distribution), inflammatory and metabolic markers worsened with disease stage: CRP rose from 1.38 to 4.93 mg/L (p<0.001, persisting after adjustment for age and BMI), HOMA-IR increased from 1.75 to 2.92, 34% had glucose metabolism alterations, HDL fell and obesity prevalence climbed from 6.3% to 91.8% across stages.
This narrative review synthesizes lipedema pathophysiology as a self-perpetuating cycle of adipocyte hypertrophy, dense interstitial fibrosis, lymphatic microangiopathy, and chronic low-grade inflammation, with M1 macrophage accumulation secreting TNF-alpha, IL-6, and MCP-1 and elevated fibrotic marker YKL-40, plus estrogen-axis dysregulation (ERbeta predominance, local estradiol excess) and mitochondrial dysfunction (reduced oxidative capacity, UCP1 downregulation).
Evidence certainty: very low (GRADE) · 1 source(s)
This review of Dercum's disease describes inflammatory and pain mechanisms overlapping with lipedema, including serum multiplex immunoassay of 37 cytokines identifying 22 present with significantly elevated IL-11, IL-28A, and IL-29, near-infrared fluorescence imaging showing abnormal fibrotic dilated lymphatic vessels, M1-like pro-inflammatory macrophage predominance, mast cell activation with substance P-induced release of histamine, TNF-alpha, and IL-1beta sensitizing nociceptors, and proposes lipedema as an estrogen-sensitive adipose disorder possibly initiated by caveolin-1 dysfunction.
Evidence certainty: very low (GRADE) · 1 source(s)
In subcutaneous adipose tissue of 11 lipedema patients versus BMI-matched controls, MIF-1 mRNA (fold-change 1.256; p=0.0485) and CD74 mRNA (1.514; p=0.0097) were elevated, with CD74 also overexpressed at the cellular level by immunohistochemistry (7.73 vs 5.18; p=0.0026), while MIF-2 was unchanged and CXCR2 was higher in controls, implicating the MIF-1/CD74 axis in inflammatory macrophage recruitment and polarization in lipedema independent of BMI.
In lipedema adipose tissue, immunohistochemistry showed increased CD45+ leukocytes (45.7 vs 28 cells/field, P<0.001) and CD68+ macrophages (19.5 vs 12.3, P=0.01) without increased CD3+ T cells, while systemic adipokines IL-6, IL-18, lipocalin-2 and leptin did not differ from controls.
High-resolution histopathology and transmission electron microscopy of lipedema adipose tissue (normal-BMI, stages 1-2) showed CD68+ macrophage infiltration increased exclusively in affected areas (similar to obesity but in normal-weight patients), along with endothelial/pericyte hyperproliferation (Ki-67+), severe endothelial barrier degeneration, calcium crystal and collagen (fibrosis) accumulation, and adipocyte cytoplasmic projections into the capillary lumen, indicating vascular and adipocyte pathology independent of obesity.
Evidence certainty: very low (GRADE) · 1 source(s)
In thigh skin and fat biopsies, lipedema (non-obese and obese) showed significantly increased CD68+ macrophages versus BMI-matched controls (p<0.005 and p<0.05) and crown-like structures absent in all controls (12.5-14% of lipedema cases), while CD3+ T-lymphocytes and CD117+ mast cells did not differ; dermal vessel number correlated with macrophage count (r²=0.45, p=0.05), and focal angiogenesis with fibrosis occurred in 30% of non-obese lipedema cases but no controls.
This review reports that lipedema tissue shows a significant increase in M2 macrophages (CD163+, CD206+), crown-like structures around dead adipocytes across all disease stages, and ECM fibrosis, with M2-conditioned media promoting adipogenesis, though one transcriptomic study (Straub 2025, n=14) found suppressed inflammation, possibly attributable to comorbidities.
Evidence certainty: very low (GRADE) · 1 source(s)
This review reports that lipedema adipose tissue exhibits hypertrophic adipocytes with CD68+ macrophage infiltration in perinecrotic crown-like structures and around vessels, mast cells and T lymphocytes in hypervascular areas, and elevated blood VEGF leading to vessel proliferation, capillary dilation, hypoxia and fibrosis, with mast cells contributing to increased interstitial fluid, adipocyte deterioration and elastic fiber fragmentation; pain is described as a hallmark symptom.
Evidence certainty: very low (GRADE) · 1 source(s)
This systematic review reports that lipedema adipose tissue and ASCs show elevated IL-8 in ASC supernatants, elevated serum IL-28A, IL-29 and IL-11, increased oxidative stress markers (malondialdehyde and protein carbonyls), and VE-cadherin downregulation suggesting vascular barrier dysfunction, indicating inflammatory and stress-related mechanisms.
Evidence certainty: very low (GRADE) · 1 source(s)
A scoping review of 25 studies reports that lipedema symptom onset clusters at reproductive hormonal milestones (puberty/adolescence in 62.2-72.0% of cohorts, worsening in pregnancy in 53.0% and menopausal transition in 67.9%), with elevated hormone-sensitive comorbidities (PCOS 12.6-17.1%, autoimmune thyroiditis up to 35.5%) and molecular findings including loss-of-function variants in AKR1C1/AKR1C2, aromatase (CYP19A1) upregulation in adipose tissue, and altered estrogen receptor balance.
Evidence certainty: very low (GRADE) · 1 source(s)
This narrative review proposes that lipedema involves a common genetic alteration—an imbalance of estradiol receptors (ERα > ERβ) in adipose tissue present in all cases—combined with physiological hormonal fluctuations (puberty, pregnancy, menopause), endocrine disruptors, and estrogen-dependent gynecological disorders, citing associations such as menstrual irregularities (43%) and PCOS (17%) in women with lipedema.
Evidence certainty: very low (GRADE) · 1 source(s)
Whole-exome sequencing in a family with autosomal dominant nonsyndromic primary lipedema identified the AKR1C1 c.638T>A (p.L213Q) variant segregating perfectly with the disease in 3 affected members (puberty onset in all) and absent in 9 unaffected members, with molecular dynamics and QSAR predicting partial loss of 20α-HSD function that may promote lipogenesis via reduced progesterone catabolism.
Evidence certainty: very low (GRADE) · 1 source(s)
A systematic review of 61 articles found that conservative therapies (ketogenic/RAD diets, compression, aquatic exercise) reduced pain and swelling (Grade 2A-2B), while tumescent liposuction showed the strongest evidence for sustained symptom improvement, mobility, and quality of life (Grade 1 recommendation), supporting early recognition with combined conservative and surgical management.
The first Dutch lipedema guidelines, framed by the ICF and Chronic Care Model, recommend a four-pillar conservative management (healthy lifestyle with weight control, graded activity training, flat-knit compression only when edema is present, and psychosocial support; manual lymphatic drainage not recommended) plus tumescent liposuction (TLA/STLA) for abnormal adipose tissue, with structured follow-up and clinical diagnostic criteria.
A systematic review of surgical and non-surgical lipedema treatments concluded that a stepwise, individualized approach is recommended—starting with optimized conservative therapy (compression, exercise, intermittent pneumatic compression) which reduces pain and edema, and progressing to reduction surgery (tumescent, water-assisted, or power-assisted liposuction) in appropriately selected patients, with liposuction showing substantial symptom and quality-of-life improvements and acceptable complication rates.
A 2022 CADTH update found zero randomized or controlled comparative trials of liposuction for lipedema and reported divergent guidelines: the UK NICE 2022 (IPG721) restricts liposuction to research contexts due to inadequate efficacy/safety data, while the US 2021 standard of care (Herbst et al.) recommends conservative treatment first and recognizes liposuction as the only technique to remove abnormal lipedema tissue, with both guidelines endorsing specialized multidisciplinary centers.
Evidence certainty: very low (GRADE) · 1 source(s)
The S2k guideline issues 60 formal recommendations advocating multidisciplinary management of lipedema combining conservative measures (compression including MCS flat-knit and intermittent pneumatic compression for pain relief, manual lymphatic drainage, exercise, Mediterranean hypocaloric or ketogenic diet, weight management), psychosocial support, bariatric surgery for BMI >=40 (or >=35 with comorbidity), and liposuction as the surgical method of choice, while explicitly recommending against diuretics.
Evidence certainty: very low (GRADE) · 1 source(s)
A systematic review of 20 studies (>1200 patients) found that multimodal management of lipedema combining conservative measures (compression, structured exercise, pneumatic compression devices, ketogenic/low-carb diet) and surgical liposuction (tumescent, PAL, WAL) yields significant improvements in pain, mobility, limb circumference and HRQoL; the LIPLEG RCT showed greater early pain reduction and mobility in the surgical group at 6 months, while combined compression plus exercise outperformed exercise alone.
A BAAPS/BAPRAS expert consensus recommends managing lipedema with conservative measures and selecting liposuction (tumescent, often staged large-volume) only when symptoms persist >12 months, functional impairment is considerable, weight is stable for 12 months, and BMI is <35 kg/m², performed in a level 2-3 hospital by an experienced surgeon supported by a multidisciplinary team including a lymphedema nurse, with mandatory preoperative psychological assessment and immediate postoperative compression.
Evidence certainty: very low (GRADE) · 1 source(s)
This narrative review synthesizes lipedema treatment modalities including ketogenic diet, exercise, compression, and liposuction alongside its pathophysiology, but does not establish a single recommended overall management protocol.
Evidence certainty: very low (GRADE) · 1 source(s)
In a US survey of 148 women with lipedema who underwent reduction surgery (61% tumescent liposuction, 38% water-assisted), 84% reported improved quality of life, 86% had reduced pain, mobility improved across stages, and 90% would repeat the procedure, though complications including new fibrosis (27.7%), adipose tissue growth in untreated areas, new lipo-lymphedema, and loose skin (75%) were reported.
A practical synthesis chapter describes tumescent liposuction (based on Klein's 1987 technique) as an effective treatment option for symptomatic lipedema refractory to conservative management, with attention to indication, technique, and perioperative care.
Evidence certainty: very low (GRADE) · 1 source(s)
This narrative review proposes, on a mechanistic/theoretical basis, that gestrinone (a 19-nortestosterone progestin acting via PRβ to increase 17β-HSD2 and inhibit 17β-HSD1 and aromatase) could reduce local estradiol accumulation and ERα overactivation in lipedema adipose tissue, but presents no clinical intervention data or outcomes in lipedema patients.
Evidence certainty: very low (GRADE) · 1 source(s)
This review proposes a mechanistic rationale for gestrinone in lipedema—based on aromatase overexpression in lipedema adipose tissue, with gestrinone hypothesized to inhibit aromatase and block estrogen receptors and adipogenesis—but presents only in vitro cell-viability data (MTT in MDA-MB-231 and Huh7 lines) and no clinical trial demonstrating efficacy in lipedema patients.
Evidence certainty: very low (GRADE) · 1 source(s)
In a survey of US women with lipedema undergoing reduction surgery, lipo-lymphedema cases showed worse functional disability scores than earlier-stage lipedema (significant inverse correlation between stage/lipo-lymphedema and LEFS score, r²=0.11, P=0.0001), and surgery improved mobility most in advanced stages (stage 3: 96%, lipo-lymphedema: 79%).
This systematic review of molecular and cellular lipedema research interprets lymphedema co-occurring in advanced stages as a consequence of associated obesity rather than a primary feature of lipedema, and proposes adding comorbidities like obesity and lymphedema to revised staging; it does not establish that lipedema itself progresses to lymphedema or quantify functional disability.
Evidence certainty: very low (GRADE) · 1 source(s)
This non-systematic review describes lipedema as having a 4-stage clinical classification with documented lymphatic dysfunction (abnormal lymphoscintigraphic patterns, impaired lymphatic transport in early stages, lymphatic aneurysmal structures) and reports impaired functional and cardiovascular parameters, but does not quantify progression rates to lymphedema or measure functional disability outcomes.
Evidence certainty: very low (GRADE) · 1 source(s)
This narrative review describes lipedema as progressing through four stages culminating in stage 4 lipolymphedema, with chronic pain, swelling, and reported lymphovascular dysfunction (e.g., decreased PROX-1, increased VEGFR-3/VEGF-C, endothelial permeability), while noting it remains unclear whether lymphatic dysfunction is cause or consequence.
Evidence certainty: very low (GRADE) · 1 source(s)
This comparative narrative review describes lipedema and lymphedema as sharing a 'trifecta' of fluid, fat, and fibrosis but in reverse temporal order (lipedema: fat→fibrosis→inflammation→fluid; lymphedema: fluid→inflammation→fibrosis→fat), and reports that lipedema shows elevated VEGF-C and PF4 with evidence of impaired lymphatic transport in cited studies, but lacks the T-cell inflammatory signature and lymphatic architectural changes characteristic of lymphedema.
Evidence certainty: very low (GRADE) · 1 source(s)
This review reports that lipedema can show delayed lymphatic flow on lymphoscintigraphy and is distinguished from lymphedema by increased subcutaneous (rather than dermal) thickness on ultrasound, and that only liposuction slows progression while CDT provides partial symptomatic relief; it does not establish that lipedema progresses to lymphedema, and notes lymphatic function was symmetric after tumescent liposuction.
Evidence certainty: very low (GRADE) · 1 source(s)
In a proof-of-principle study of 5 women with Stage 1-2 lipedema and concurrent early Stage 0-1 lymphedema, multimodal physical therapy reduced pain (VAS 4.6 to 0.0) and improved functional scale scores (PSFS 4.5 to 8.3), with the enrollment criteria indicating coexistence of lipedema and early-stage lymphedema affecting functional mobility.
Evidence certainty: very low (GRADE) · 1 source(s)
This review proposes that lipedema patients (including those with BMI <30 kg/m²) can develop subclinical and clinical bilateral systemic lymphedema in the lower limbs, which worsens and progresses to the trunk and upper limbs as obesity develops, and contributes to increased limb volume requiring exclusion before liposuction.
Evidence certainty: very low (GRADE) · 1 source(s)
In a scoping review of 53 studies on lipedema functioning mapped to the ICF framework, lymphatic/immunological system functions (b435) were assessed in 34% of studies and fatigue was reported in ~75% of patients, but the 'activities and participation' domain (e.g., walking d450, employment d850) was addressed in only 17% of studies, and 50/53 studies were rated as methodologically 'weak'.
Evidence certainty: very low (GRADE) · 1 source(s)
In a Swiss referral cohort of 381 lipedema patients, chronic vascular disease was the dominant comorbidity affecting 86.2% (predominantly chronic venous disease rather than atherosclerosis), and comorbidity burden increased with stage on univariate analysis (OR 1.59, 95% CI 1.39–1.81) but lost independent significance after adjusting for age and BMI in multivariate regression.
In a cohort of patients undergoing endothermal ablation for chronic venous insufficiency, those with concomitant lipedema had worse baseline CIVIQ-20 quality-of-life scores (median 61.0 vs 46.0, p=0.001) and significantly smaller post-procedure improvement (4.0 vs 13.5 points, p=0.012); lipedema was an independent predictor of worse postoperative CIVIQ-20 (β=12.44, p<0.001), and venous symptoms attributable to lipedema remained unchanged by venous intervention.
In a case series of 189 women undergoing lipedema reduction surgery, varicose veins were present in 48.6% and spider veins (telangiectasias) in 24.5% as documented comorbidities, alongside joint hypermobility (50.5%) and arthritis (29.1%).
In a cross-sectional study of 82 clinically confirmed lipedema patients in Saudi Arabia, varicose veins were reported as a comorbidity in 10% and observed on physical examination in 36%, telangiectasias were present in 64%, while deep vein thrombosis history was rare (4%) and pulmonary embolism 3%.
This review traces the historical evolution of liposuction from its first experimentation by A. and G. Fischer in the 1970s, describing its technical transformations and clinical applications including the reconstructive treatment of lipedema, lipomas, and lymphedema, with a reported low complication rate.
A narrative review of 19 studies (>1,500 patients, 1996-2024) accompanying a 24-patient Latin American case series notes the largest published series was Fischer et al. (n=691) and that maintained benefits have been documented at 12-year follow-up (Baumgartner et al. 2021), while the Lima, Peru series represents the only Latin American report in a literature dominated by European series.
This review states that lipedema was first identified in 1940 by Allen and Hines at the Mayo Clinic and describes its clinical staging (stages I-IV, types I-V) and surgical treatment options including tumescent and water jet-assisted (WAL) liposuction that preserve lymphatic vessels.
Evidence certainty: very low (GRADE) · 1 source(s)
This iconographic review notes that lipedema received formal medical recognition by Allen and Hines in 1940 and that contemporary treatment includes both conservative and surgical methods, while tracing artistic depictions of lipedema-compatible morphology from prehistoric Maltese sculptures (~3000 BC) and ancient Egyptian reliefs to modern works.
Evidence certainty: very low (GRADE) · 1 source(s)
In a survey of lipedema patients comparing self-reported stages, more advanced stage (3-4) was associated with higher rates of depression (48.3% vs 34.8%, p<0.001), social isolation (staying home 64.3% vs 44.4%), life dissatisfaction (35.7% vs 22.0%), and loss of mobility, while psychological burden such as inferiority complex (72.8%) and constantly thinking about lipedema (73.4%) was high across all stages.
This narrative review synthesizing 25 references reports that lipedema patients show greater emotional dysregulation and higher anxiety (Al-Wardat: 26 patients vs 26 controls via DERS/HAM-A), significant behavioral disturbances versus overweight/obese controls (Chachaj et al.), depressive/anxious symptoms associated with comorbid fibromialgia (Cagliyan Turk et al.), occupational limitations in 51–73% of respondents (Clarke et al.), and that liposuction significantly reduced depressive symptoms and improved quality of life and body image (Arndt et al.).
Evidence certainty: very low (GRADE) · 1 source(s)
In a systematic review and meta-analysis of cross-sectional cohorts, women with lipedema showed reduced HRQoL across all SF-36/RAND-36 domains versus population norms, with the largest deficits in energy/fatigue (43.50 vs 59.4), bodily pain (51.77 vs 77.4), role physical (51.10 vs 82.4), and general health (49.64 vs 73.1), plus impaired emotional well-being (64.19 vs 73.2) reflecting frequent anxiety/depression.
In a prospective study of lipedema patients undergoing power-assisted liposuction, PHQ-4 total scores fell from 4.47 (mild depression, above population norm) to 2.10 (p<0.001), with anxiety subscale dropping 2.47→0.93 and depression subscale 2.00→1.17, while quality-of-life satisfaction (FLZM health module 45.77→88.00), self-esteem (RSES 29.93→33.33), and emotional stability all improved significantly postoperatively.
In a cross-sectional survey of women with lipedema (n=112), WHOQOL-BREF averaged 3.12 (1-5 scale) and life satisfaction (SWLS) averaged 3.63 (below midpoint), with symptom severity explaining 13.9% of QoL variance; psychological flexibility (AAQ-II β=0.26) and social connectedness (SCS-R β=0.37) independently predicted QoL after controlling for symptom severity, raising explained variance to 44.4%.
In a national Swedish survey of women with lipedema, RAND-36 scores were 25-35 points below the age-matched general female population across all subscales (largest gap in physical role functioning, ~43 points lower in ages 60-79; smallest in emotional well-being, ~10 points), with worse physical and social functioning at higher lipedema stages and a self-reported depression prevalence of 13.5%.
In 511 lipedema patients, PHQ-9 averaged 10.84±6.39 with 54% at risk of moderate-to-severe depression, WHOQOL-BREF global score averaged 60.5±16.02 (lowest in physical 54.54 and psychological 51.91 domains), and quality-of-life impairment correlated with disease stage (r=0.55, p<0.001) and inversely with depression score (r=-0.775, p<0.0001).
In a survey of lipedema patients, RAND-36 quality of life was significantly lower than the general Dutch female population (59.3 vs 74.9, p<0.001) and EQ-5D-3L was reduced (66.1 vs 85), with 42.0% reporting anxiety/depression and 74.1% reporting pain/discomfort (vs 31.1% in the general population).
In a Swiss cohort of 239 lipedema patients assessed with validated questionnaires, 64.4% had anxiety (HADS≥8), 23.4% had depression (HADS≥8), and low quality of life was found in 71.5% (PCS-SF36) and 67.4% (MCS-SF36), with none of these psychosocial parameters differing significantly across disease stages (p>0.5).
The authors propose a clinical-ultrasonographic diagnostic algorithm for abdominal lipedema using maximum criteria (symmetric abdominal fat deposition + ultrasonographic evidence + inelastic skin), major criteria (pain on palpation + non-response to diet/exercise), and minor criteria (easy bruising + heaviness), correlating abdominal involvement with lipedema stage (31% in stage II, 70% in stage III).
This systematic review of 61 articles found that lipedema diagnosis relies largely on clinical features from observational cohorts, case series, and expert consensus with few randomized trials, and concluded that standardized diagnostic criteria and validated patient-reported outcomes are still lacking.
This study proposes adding two intermediate stages (1.5 and 2.5) to the classical 3-stage lipedema system and objectively characterizes progression using standardized item-by-item physical exam (modified Wold criteria), Beighton hypermobility score, infrared thermography, and bioimpedance spectroscopy, finding that BMI increases linearly with stage (r2=0.5628, p<0.0001), peripheral hypothermia and total body water rise with stage, L-Dex lymphedema risk is significantly elevated only at stage 3, and pain is present in 70% at stage 1 (not obligatory early).
The first Dutch lipedema guidelines define clinical diagnostic criteria requiring all five Wold anamnestic criteria (disproportionate fat distribution, poor fat response to weight loss, pain/easy bruising, touch sensitivity/extremity fatigue, no pain reduction with elevation) plus at least one regional physical-examination criterion pair, with extra criteria (bimanual palpation pain, distal-knee lipomas) compensating when up to two criteria are absent, while noting the absence of objective diagnostic criteria.
This narrative review describes the lipedema clinical classification into types I-V and stages I-IV, lists differential diagnoses (lymphedema, phlebedema, lipohypertrophy, Dercum's disease, Launois-Bensaude lipomatosis), and reports proposed imaging cut-offs (e.g., high-resolution ultrasound subcutaneous thickness 11.7 mm pretibial, DXA leg-fat/total-fat ratio 0.383), while identifying the absence of an objective, easy-to-perform diagnostic imaging test as a critical gap.
Evidence certainty: very low (GRADE) · 1 source(s)
In a systematic review of 32 studies (1154 patients), imaging methods proposed for characterizing lipedema include ultrasound (increased subcutaneous adipose tissue), lymphoscintigraphy (slowed lymphatic flow, inter-limb asymmetry), CT (symmetrical bilateral soft tissue enlargement without skin thickening or edema), MRI, MR lymphangiography (enlarged lymphatic vessels up to 2 mm), and DXA (leg fat mass/BMI ≥0.46 or leg fat/total fat ≥0.384), but their overall diagnostic performance was limited.
In a cross-sectional survey of 969 Spanish lipedema patients, diagnoses used the Schingale type I-IV classification (type III 41.7%, type IV 36.8%, type II 17.8%, type I 3.7%) and a modified Wolf/Herbst 13-criteria symptom scale; the authors validated a threshold of ≥6 of 13 symptoms (Mann-Whitney p=0.666 showing no distributional difference between diagnosed and undiagnosed groups), and diagnosis often required multiple consultations (51.2% needed ≥3 specialists).
This narrative review describes lipedema as a clinical entity diagnosed by clinical presentation and differentiated from obesity and lymphedema, but notes it remains poorly characterized with frequent misdiagnosis and a lack of high-quality studies precisely defining its features.
In a Swiss cohort of 381 lipedema patients classified by type (I-V) and stage (1-4), advanced stage correlated with age and BMI, but a Stemmer sign was positive in only 4.0% and validated questionnaire scores (HADS, BPI, FSS, SF-36) did not differ significantly between stages (p>0.5), revealing a dissociation between morphological stage and symptom burden.
This selective review states that lipedema diagnosis is exclusively clinical with no specific biomarker available, complementary exams used only to exclude differential diagnoses, and notes that diagnosis remains challenging due to heterogeneous presentation and the absence of objective characterization instruments; in Germany liposuction was approved for stage III patients.
Evidence certainty: very low (GRADE) · 1 source(s)
In a Spanish cohort of 1,803 lipedema patients, 46.6% were classified as Schingale stage IV or V, and the authors propose a novel clinical examination approach (including signs such as bilateral trochanteritis and ligamentous hyperlaxity) to support rapid diagnosis.
In an observational study of 360 Italian women with lipedema, structured clinical evaluation applied a 3-stage staging system and anatomical type classification (1-5), with stage distribution of 39.7% stage 1, 40.0% stage 2, and 20.3% stage 3, and anatomical type 3 most prevalent (89.7%), while clinical signs including pinch pain (99.4%), subcutaneous nodules (98.9%), and progressive pain scores by stage (p<0.001) were documented.
A retrospective study of 34 women with lipedema using high-frequency B-mode ultrasound (10-15 MHz) across three platforms proposes a new qualitative Lipedema Dermal and Hypodermal Classification (LDHC) with four stages distinguishing preserved architecture (LDHC 1), bulging architecture (LDHC 2), inflammatory phenotype with hyperechoic nodules (LDHC 3), and fibrotic 'marbled' phenotype with septal verticalization (LDHC 4), intended to complement existing anatomical and functional classifications.
This review describes lipedema clinical presentation using a classification of 5 types by anatomical fat distribution (I: hip/buttocks; II: hip to knee; III: hip to ankle; IV: also arms in ~80% of women; V: calf only) and 4 stages (I: smooth skin with enlarged hypodermis; II: palpable nodules with peau d'orange; III: deforming fat masses with folds; IV: lipolymphedema with positive Stemmer sign), and notes that only 46.2% of surveyed vascular consultants could recognize the disease.
Evidence certainty: very low (GRADE) · 1 source(s)
In a cross-sectional study of 115 Saudi patients with lower-limb edema, clinical diagnosis of lipedema used a structured assessment including signs (cuff/collar sign, Stemmer sign, telangiectasias, non-pitting orthostatic edema), severity grading 1-4 and anatomical type classification 1-5; clinical criteria confirmed lipedema in 71% (82/115), grade 2 was most common (31%), type 3 (hip-to-ankle) predominant (47%), and the cuff/collar sign correlated with advanced stages (80% of those with the sign were ≥grade 2).
The German S1 guideline defines lipedema diagnostic criteria (onset at puberty/pregnancy/menopause, disproportional adipose proliferation sparing hands and feet, periarticular cuffing, palpation hypersensitivity, increasing edema, negative Stemmer sign) and classifies it by three morphological stages and by anatomical location, with differential criteria distinguishing it from lipohypertrophy, obesity, and lymphedema.
Using ICG lymphography in 45 women with lipedema classified by different types and stages, lymphatic function (dye transit speed) correlated with symptom duration (T25' vs duration r=-0.469, p=0.037) rather than with lipedema stage or fat accumulation, and a linear lymphatic pattern was found in 100% of patients with no major anatomical abnormalities.
This author response clarifies that non-invasive 3T MR lymphangiography detects subcutaneous adipose tissue edema in lipedema, while contrast-enhanced T1-weighted MRI can identify fibrosis (early enhancement = developing granulation, late enhancement = mature fibrosis) and 23Na-MRI can quantify tissue sodium, supporting MRI's role in characterizing lipedema and lymphedema.
Evidence certainty: very low (GRADE) · 2 source(s)
This review reports that high-resolution ultrasound distinguishes lipedema (increased subcutaneous thickness; cut-offs 11.7 mm pretibial, 17.9 mm anterior thigh, 8.4 mm lateral leg) from lymphedema (increased dermal thickness with reduced echogenicity), DXA differentiates lipedema via leg-fat/total-fat index (cut-off 0.383) and BMI-adjusted leg fat (cut-off 0.46), MR lymphangiography shows dilated lymphatic vessels with a 'beaded' appearance, and lymphoscintigraphy reveals delayed lymphatic flow with frequent inter-limb asymmetry, while noting that no easy, objective diagnostic imaging test currently exists.
Evidence certainty: very low (GRADE) · 1 source(s)
In 30 women with clinically confirmed lipedema undergoing 99mTc-nanocolloid lymphoscintigraphy, 60% showed no overt lymphatic damage while 40% showed confirmed lymphatic alterations indicating coexisting lipo-lymphedema, with lymphoscintigraphy used to detect lymphostatic components and guide surgical decisions rather than for routine lipedema diagnosis, which remains clinical.
In 40 women with clinically diagnosed lipedema, ICG lymphography classified 85% as MDACC Stage 0 (normal lymphatics) and showed a distinguishable pattern (linear vessels without dermal backflow) versus the extensive dermal backflow of bilateral lymphedema, with only 5% having lymphedema and a negative Stemmer sign consistently corresponding to normal lymphatic morphology.
High-frequency B-mode ultrasonography in 34 women with lipedema differentiated lipedema from obesity, where obese patients showed predominantly deep hypodermal thickening with preserved linear septa and layered architecture, while lipedema showed septal disruption, and a four-tier qualitative classification (LDHC) was proposed based on dermal and hypodermal structural patterns.
MR lymphangiography with intracutaneous gadoteridol distinguished pure lipedema from lipo-lymphedema: epifascial high-signal edema on T2-TSE was present in 100% (16/16) of lipo-lymphedema limbs but 0% (0/10) of pure lipedema limbs, while subcutaneous fat was thickened in all 26 limbs; contrast peak in lower-leg lymphatics was delayed in lipo-lymphedema (peak 45–55 min) versus lipedema (peak 35 min), and 60% of pure lipedema limbs showed subclinical dilated lymphatics despite no T2 lymphedema signal.
In a systematic review of six diagnostic modalities, MRI/MRL achieved 100% sensitivity (calf subcutaneous water area) and reliably differentiated lymphedema from lipedema, with non-contrast MRL identifying increased subcutaneous adipose tissue in lipedema and epifascial collections in lipolymphedema; CT showed 95% sensitivity/100% specificity for lipedema with subcutaneous honeycombing being 100% specific for lymphedema and absent in lipedema; whereas lymphoscintigraphy (lymphedema gold standard) could NOT distinguish lipedema from lymphedema since lymphatic changes occur in both.
Evidence certainty: very low (GRADE) · 1 source(s)
Lower-limb lymphoscintigraphy did not differentiate lipedema from non-lipedemic overweight/obesity matched by leg volume: abnormal scans (83% vs 96.8%), dermal backflow (5.9% vs 9.7%), absent inguinal nodes (0% in both), and mean lymphoscintigraphy score (1.686 vs 2.323) showed no statistically significant differences.
In a case series of 7 women who underwent bariatric/metabolic surgery (5 RYGB, 2 sleeve) with substantial weight loss (%EWL 27.4-104.2%; BMI reduction 4.0-24.5 kg/m²), lipedematous nodular fat remained voluminous and symptoms (pain, tenderness, easy bruising, edema, limb heaviness) persisted in 100% of cases, with weight regain accompanied by increased limb volume and worsening symptoms.
In a national survey of 707 women with a lipedema phenotype, 15.7% had undergone gastric bypass and 93.8% used diet, yet 52.2% reported no benefit from diet/exercise and only 16.0% reported complete improvement, indicating limited symptom relief from weight-loss approaches.
This narrative review reports that bariatric surgery is ineffective at reducing pathological lipedema fat deposits (per the German S2K guideline), although it may control comorbid obesity and improve metabolic health, while liposuction (WAL/tumescent) produces sustained reductions in pain and leg volume (e.g., 6.9% volume reduction and pain VAS dropping from 7.2 to 2.1 at 6 months in Rapprich et al.).
Evidence certainty: very low (GRADE) · 1 source(s)
In a retrospective study of lipedema patients undergoing multistage lymph-sparing liposuction, BMI decreased by a median of 2.7 kg/m2 and patients with BMI ≤35 had greater symptom (VAS composite 51.6% vs 25.3%) and conservative-therapy-need reduction than those with BMI >35, but liposuction volume did not correlate with symptom or treatment-need reduction; the study did not evaluate bariatric surgery or substantial weight loss as the intervention.
In a 7-week eucaloric ketogenic (LCHF) diet pilot study of women with lipedema, weight loss of −4.6±0.7 kg was accompanied by reduced waist (−4.3 cm) and hip (−2.2 cm) circumferences but NO significant thigh reduction (p=0.20), and pain reduction at week 7 did not correlate with weight loss (r=0.283, p=0.46), indicating lipedematous fat resists weight-loss-driven volume change and symptom benefits appear independent of weight loss.
This narrative review of lipedema comorbidities lists thyroid disorders among reported associated conditions but does not provide a quantitative or adjusted test of an independent lipedema-thyroid association.
Evidence certainty: very low (GRADE) · 1 source(s)
In a cross-sectional study of 1001 Spanish women with lipedema, thyroid disease was significantly more prevalent than in the general female population (OR=2.21; 95% CI: 1.8-2.6).
In a weighted National Inpatient Sample cohort of obese women, hypothyroidism was more prevalent among patients with lipedema than without (23.3% vs 19%, p<0.01), though this was an unadjusted comorbidity comparison rather than a multivariate-adjusted test.
In an exploratory retrospective study of 45 women with lipedema versus 40 age-matched controls, platelet indices PDW and MPV were numerically higher in the lipedema group but showed no statistically significant between-group differences in any CBC parameter after correction for multiple comparisons, arguing against these as standalone diagnostic markers.
In 151 women, those with lipoedema (N=90) reported significantly higher LYMQOL-leg burden scores for symptoms (p=0.003), appearance (p=0.003) and mood (p=0.011), and worse LSIDS-L neurological, biobehavioral and resource scores than those with bilateral leg lymphoedema (N=61), indicating distinguishable HRQoL profiles despite similar symptoms.
In 24 women with lipedema undergoing liposuction, perioperative ultrasound measured superficial subcutaneous fat (D1) thickness, which decreased significantly from 9.9 mm preoperatively to 6.3 mm postoperatively, but the study assessed treatment monitoring rather than diagnostic classification of lipedema.
Evidence certainty: very low (GRADE) · 1 source(s)
In women with clinically diagnosed lipedema, ultrasound and elastography were used to measure subcutaneous tissue thickness and stiffness for treatment monitoring, but the study assessed treatment-related changes rather than diagnostic or classification accuracy.
In a cohort of 50 women with confirmed lipedema undergoing tumescent liposuction, quantitative ultrasound elastography (QUS) and B-mode ultrasonography were used to measure postoperative tissue stiffness (e.g., 14.8 ± 3.1 kPa) and fibrotic changes, though the study evaluated serrapeptase efficacy rather than diagnosis.
A proposed mechanistic framework for lipedema cites a 35–40% comorbidity with fibromyalgia and characteristic histaminergic peripheral sensitization generating neuropathic pain in gluteofemoral adipose tissue.
In a cross-sectional comparison of obese women with lipedema (n=30) versus obesity alone (n=29), the lipedema group reported higher pain intensity, lower pressure pain thresholds in arms and legs, greater pain interference, and higher pain catastrophizing, but the study did not assess fibromyalgia or other named chronic-pain diagnoses.
In an exploratory cross-sectional study of 118 women, lipedema patients showed higher neuropathic pain prevalence (42% vs 21%) and higher painDETECT/LANSS scores than lymphedema patients, with strong correlations between pain intensity, catastrophizing, and anxiety, but the study did not assess fibromyalgia specifically.
This narrative phlebology review describes lipedema as a systemic vascular-lymphatic-inflammatory disorder in which delayed diagnosis leads to chronic pain and functional impairment, but it does not test an association between lipedema and fibromyalgia or other chronic-pain conditions.
In a retrospective analysis of ultrasonographic images from 34 women clinically diagnosed with lipedema, the article states the etiology remains uncertain but may be related to genetic and female hormonal factors, without testing this relationship.
Evidence certainty: very low (GRADE) · 1 source(s)
In a study of PBMT applied before dermolipectomy in three lipedema patients, the article notes that lipedema predominantly affects women during hormonal phases (menarche, pregnancy, menopause) and reports laser-induced upregulation of aromatase (CYP1A1), a hemoprotein involved in hormone metabolism, without directly testing hormonal or hereditary causes of onset.
Evidence certainty: very low (GRADE) · 1 source(s)